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INTRODUCTION 
Dengue virus is increasingly recognized as one of the world’s 
major emerging infectious tropical diseases1.According to WHO, Dengue 
fever or Dengue haemorrhagic fever is considered as the   second most 
important tropical disease next to malaria2 .Dengue in recent years has 
become a major international health problem.  Annually there are 100 
million new dengue viral infections reported worldwide with 5 lakh cases 
of Dengue haemorrhagic fever(DHF) and Dengue shock syndrome(DSS). 
There are around 30000 deaths every year which is mostly among 
children2,3,4. DHF/DSS is known as one of the leading causes of mortality 
and morbidity among school going children in Tropical and Subtropical 
countries5. 
  In India, dengue fever has been known for the past 2 centuries.  In 
India the virus was first isolated in 1945.All the four serotypes are 
endemic in India6,7. In South India all 4 serotypes of dengue were isolated 
in Vellore between 1956 &1960. Later on it started to be reported from 
other parts of India. 
Dengue virus is a single stranded RNA virus with four serotypes. 
They are DEN1, DEN2, DEN3 &DEN4. Infection with one serotype of 
Dengue does not confer cross protection against the other serotype. On 
subsequent infection it may lead to serious forms of disease like Dengue 
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haemorrhagic fever and Dengue shock syndrome through immuno–
pathological enhancement8,7.   
Clinically Dengue infection causes a wide spectrum of illness 
ranging from undifferentiated dengue fever, Dengue haemorrhagic fever 
and Dengue shock syndrome which can finally lead to death7. 
  Commonly used diagnostic methods for Dengue are viral isolation, 
RT-PCR and serological methods. Viral isolation is a time consuming 
and fastidious process that requires specialized laboratory equipments and 
experienced personnel. RT-PCR even though significantly reduces the 
processing time and detects the virus in early stage these methods remain 
expensive and technically difficult particularly in laboratory settings of 
the developing world9. 
       Serological diagnosis of Dengue has many advantages like more 
flexibility, wide availability of reagents, low cost and requirement of less 
equipments7. One of the definite methods to diagnose early Dengue 
infection is to detect specific antigen which directly correlate with 
underlying viremia and pathogenesis of infection10,9. 
       There is no specific treatment or vaccine for Dengue infection.   
Hence in view of its life threatening complications and increased 
mortality rate, it is imperative to have rapid and sensitive laboratory 
methods for early recognition of disease. This helps to identify cases, 
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initiate treatment at the earliest and to reduce the complications 
associated with it.  Apart from serological parameters, haematological 
profile and biochemical tests are also helpful as diagnostic markers in the 
detection of Dengue infection. 
 
In view of the increased occurrence of Dengue and its complications, the 
study is undertaken   to look for seropositivity of Dengue among patients 
attending tertiary care hospital with categorisation and   comparatively 
evaluate the performance of ELISA and rapid card in the detection of 
dengue antigen and antibody.   
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
AIM AND OBJECTIVES 
Aim:   Multivariate analysis of Dengue   in a tertiary care hospital. 
Objectives of the study: 
1. To study the  significance of seropositivity  of  Dengue  in a tertiary 
care hospital.  
2. To differentiate serologically between primary and secondary 
dengue.  
3. To detect Dengue NS1 antigen, Dengue IgM and IgG antibody by 
rapid card method and ELISA technique.  
4. To compare and evaluate the efficacy of rapid card with 
immunocapture   ELISA in the diagnosis of dengue infection. 
5. To correlate Dengue clinically along with haematological and 
biochemical markers. 
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REVIEW OF LITERATURE 
History:  
• First description of dengue was given by Benjamin Rush in 178011. 
• Mosquito borne transmission of infection by Aedes aegypti was 
demonstrated in 1903 by Graham, by Bancroft in 1906 and by 
Cleland et al in 191812. 
• Viral etiology was demonstrated in 1906 by Bancroft. 
• Dengue viral serotypes were discovered in 19441. 
• Dengue haemorrhagic fever was described after worldwar –II. 
• First epidemic of DHF was reported from patients with 
haemorrhagic disease during an epidemic in Manila in 1956. 
• Sabin and his colleagues showed   that virus strains from 3 
geographical areas like Hawai, New guinea and India were 
antigenically similar12 . 
• The strain isolated from Hawai  was called as DENV-1. 
• Strain isolated from NewGuinea  was called as DENV-2. 
• DENV-3 & DENV-4 were isolated later on during epidemics in 
Manila. 
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Epidemiology:  
The first reported major epidemic was in 1779-80 in Asia, Africa 
and North America which indicated that these viruses and their mosquito 
vector had world wide distribution in tropics for more than 200 years7. 
Earliest record of Dengue was seen in Chinese encyclopedia of disease 
symptoms and remedies first published during the JIN dynasty and again 
in 992 in northern sung dynasty. The disease was called as “water 
poison” by the Chinese and was thought to be connected with flying 
insects associated with water12. 
             Global pandemic of Dengue began in South East Asia .It was first 
reported from Batavia in Jakarta of Indonesia12 and intensified after world 
war II. Outbreaks of dengue fever epidemics were documented 
sporadically with a long gap of 10-30 years. In Southeast Asia, epidemic 
dengue haemorrhagic fever was first reported in 1950s. In 1975, it 
became a leading cause of hospitalization and death among children in 
many countries, with a case fatality rate of 1-5%13,14. After a long interval 
of 10-40 years second pandemic occurred in Asia in 1980 including 
China and Taiwan. Dengue viruses were reintroduced in the pacific 
regions after 25 years   in the early 1970s 12. 
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Recent epidemic in Srilanka and India was associated with multiple 
serotypes but DEN-3 serotype was predominant and different from the 
previous occurrence.  In other countries of Asia where DHF is endemic, 
the epidemics have become progressively larger in last 15 years.  
Epidemics reported around the world: 
• Chartertower,Australia-1897 
• Beirut- 1910 
• Taiwan -1916 
• Greece- 1928 
• Taiwan-193112 
 Currently dengue fever causes more illness and death than any other 
Arboviral disease of humans.The incidence has increased over the last 50 
years with 2.5 billion people now living in dengue endemic areas12. 100 
million cases are reported every year worldwide with 5 lakh cases of 
dengue haemorrhagic fever and dengue shock syndrome. Around 30,000 
deaths /year are reported which is mostly among children of 1to 14 years 
of age13. 
India:  The encounter of Dengue in India is interesting and intriguing. 
The clinical entity of dengue fever has been known for the past two 
centuries. Initially it was restricted to east coast of India which later 
affected most parts of India. It has been endemic in several parts with 
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interspersed Epidemics. The first major Epidemic in India was reported 
from Madras in 1780. The dengue virus was first isolated in Calcutta in 
1944.Isolation of serotypes 1&4 was in 1964 followed by serotype 3 in 
1968. In 1998 Dengue virus subtype 3 of Serotype 3 arose from India and 
spread to the world15 .Since then serotypes were isolated from Vellore, 
Pondicherry, Chennai, Mangalore, Kolkata, Assam, Lucknow, Delhi & 
Haryana.  Major outbreak of dengue in India was during October 2002 to 
December 2003. Dengue   seems to be an emerging disease in TamilNadu 
according to Moorthy et al 200916 and in other parts of India where 
Dengue fever & Dengue haemorrhagic fever have occurred. 
Epidemics   Reported in India: 
Calcutta-1963, Vishakapatnam-1964, Vellore -1968, Ajmeer-1969, 
Kanpur-1969, Delhi- 1970, Rajasthan- 1985, Delhi- 1996, Delhi -2003, 
2006, 201016,14 
Dengue on rise: 
Increased incidence and emergence of epidemic DHF is due to  
1. Ecological changes 
2. Massive human movement during World War II 
3. Economic development 
4. Unplanned and uncontrolled population growth 
5. Uncontrolled urbanization. 
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6. Air travel by humans. 
7. Lack of effective mosquito control in dengue endemic areas17,18,12,19 
8. Sub standard housing and inadequate water supply, sewage and waste   
    management systems20. 
9. Presence of all four serotypes with secondary infection of a different  
    serotype in the Host21,22,17,12. 
Dengue virus: 
  It is an enveloped positive sense ssRNA virus of 35- 40 nm 
diameter belonging to the Genus Flavivirus and family Flaviviridae. 
Genus has about 70 distinct viruses. Out of 70, 13 viruses are causing 
disease in humans and 3 are found to cause increased mortality. 
Genomic structure: 
The genomic RNA is approx. 11 kb in length. It is  composed of 3 
structural  protein genes that encodes nucleocapsid or core protein , a 
membrane associated (m) protein ,envelope (e) protein and 7 non-
structural proteins  namely NS1,NS2a,NS2b,NS3,NS4a,NS4b,NS5. NS1 
protein is secreted from virus infected cells19. NS1protein is involved in 
virion morphogenesis, NS2A and NS3 Protein has virus specific protease. 
NS3 has helicase activity. The nucleocapsid core is encapsulated by a 
lipid bilayer membrane.It has 180 copies of membrane proteins and 180 
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copies of envelope proteins which is anchored to it. DENV envelope is 
found to be the dominant antigen23. 
NS1 is 55KDa membrane bound glycoprotein whose function has not 
been fully determined. NS1 protein is responsible for inducing the soluble 
complement fixing antigen which is detected in virus infected cells .It is 
said to contribute to the pathogenesis of Dengue 24,1. In children elevated 
NS1 plasma concentration early in illness are associated with more severe 
disease reflecting high viral burden7.  
Serotypes of Dengue: 
There are 4 serotypes of dengue DEN-1, DEN-2, DEN-3&DEN-4 
depending on antigenic and genetic characterization, 19&16 .DEN 1and 3 
serotypes share antigenic determinants. Close relation between DEN1 and 
4 serotypes has been proved by cDNA hybridization probe. DEN 2 
serotype alone shows low sequence homology with all other serotypes. 
Dengue epidemic results from introduction of new serotype in 
areas where already one serotype exists. Asymptomatic to symptomatic 
infection ratio in dengue viral infection varies with virus strain, age and 
immune status of the population.   
Route of transmission: 
        Dengue fever is transmitted by the bite of the principal vector 
mosquitoes called Aedes aegypti followed by other secondary vectors 
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like Aedes albopictus ,Aedes scutellarius & Aedes polynesiensis. In India 
the common vector is Aedes aegypti25. 
Aedes aegypti is an African mosquito. Slave trade between Africa 
and America and the resulting commerce were responsible for the 
introduction and widespread geographic distribution of Aedes aegypti in 
the new world during17th, 18th &19th centuries.It has black and white 
stripes on the body. Aedes mosquitoes are other wise called as “Tiger 
mosquitoes”. 
The life span of mosquitoes is increased by moderate temperature 
and increased humidity .There is a year round transmission between 350N 
and 350S with increased transmission during rainy season. With 
increasing spread of vector mosquitoes throughout the tropics and sub 
tropics large areas of the world have been vulnerable to the introduction 
of dengue viruses through air travel by infected humans18. 
Aedes Mosquitoes has a life span of 1 to 4 weeks. Following 
infection by dengue virus it requires an extrinsic incubation period of 1 to 
2 weeks to become infective to humans. Even though infected it does not 
suffer from the disease. Sexual transmission occurs from male to female 
and not vice versa. Females mate only once in their lifetime and can 
produce eggs at intervals throughout their life .They require blood as the 
source of protein for maturation of eggs.  Digestion of blood meal and 
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simultaneous development of eggs takes 2-3 days in the tropics but longer 
in temperate climates. Female mosquitoes lays 30 -300 eggs at a time.  
Transovarian transmission7 in mosquitoes leads to propagation of virus 
to their progeny and it acts as reservoir for virus maintenance during Inter 
epidemic periods. Eggs are laid above the water surface and hatch only in 
water which can happen even in flower vases, water storage jars and 
rainwater collected in small cups, tyres etc26, 19.If left dry they remain 
viable for many weeks. 
 Adult mosquitoes are indoor daytime biting mosquitoes. Females 
are said to be nervous feeders.Disruption of the feeding process of 
mosquitoes takes place even at the slightest movement of the biting 
person. Aedes will often feed on several persons for a single meal. During 
this single blood meal, if the mosquito is infective it may transmit dengue 
virus to multiple persons in a short period of time even if they only probe 
without taking blood. Because of this behavior it can affect all the family 
members which makes it an effective Epidemic vector12,19 .Mosquitoes 
are normally  attracted by body odours,CO2 and  heat emitted from 
animals/human beings18. 
Adult mosquitoes normally shelter indoor and bite at an interval 1-
2 hrs particularly during early morning and late afternoon. The 
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commonest   biting area preferred are over the ankles and exposed parts 
of neck.  
Other modes of transmission: 
Needle stick injuries1. 
Through blood transfusion in endemic areas during the viremic 
period27,28. 
Vertical transmission of dengue virus to neonates whose mothers had an 
onset of primary /secondary dengue fever upto 5 weeks before delivery 
has resulted in acute neonatal dengue manifesting as fever, apnoea, 
mottling, hepatomegaly and decreased platelet count1. 
Endemic transmission: In endemic countries 1/20 houses   may contain   
infected mosquitoes1. 
Viral replication: 
DENGUE DISEASE 
“A TICKING TIME BOMB OF HUGE EPIDEMIC POTENTIAL” 
Following vector bite ,incoming genomic RNA serves directly as 
messenger RNA .It has a large open reading frame which  is translated 
completely from its 5’ end to produce a large precursor  polyprotein 
which is again cleaved to produce  individual proteins. About ¼th length 
of genomic RNA from 5’ end encodes 3 structural proteins and 3’ end 
encodes for non-structural proteins. Premembrane precursor protein is 
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cleaved and matures to form ‘M’ (membrane). NS3&NS5 proteins form 
RNA dependent RNA polymerase complex. NS3 is responsible for co- 
translational cleavage of nascent polyprotein that yields the NS protein 
whereas cellular signal peptidases affect other primary cleavage. 
 
 
     
 
 Replication occurs in the perinuclear foci leading to synthesis of 
complementary minus strand which is the template for synthesis of more 
positive strands during infection. Virion assembly takes place mainly on 
the endoplasmic reticular membrane in vertebrates and in plasma 
membrane in invertebrates. Fully formed cell is released usually by cell 
lysis. 
Pathogenesis and Immunological reaction  
  After the bite of an infected mosquito, the virus replicates in local 
lymph nodes and within 2 to 3 days disseminates through the blood   to 
tissues.  Interstitial dendritic cells located in the epithelia are believed to 
constitute the first line of innate host immune response against invasion 
of dengue virus. Since phagocytic cells are serving as first line of defense, 
most of the infections are asymptomatic. Virus circulates in blood for 5 
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days in infected monocytes and macrophages and to lesser degree in B 
cells and T cells. It also replicates in the skin, spleen lymphoid cells and 
macrophages1. Macrophage inflammatory protein-1α has a pathogenic 
role in dengue virus infection8. 
 Infection of monocyte and macrophage is central to the 
pathogenesis of Dengue fever and origin of Dengue haemorrhagic fever 
or shock syndrome16. First infection with any of the dengue serotypes 
results in self limiting febrile illness. Recovery from first infection is 
usually accompanied by generation of immunological responses. Hence 
secondary infection with a heterotypic virus will result in severe illness. 
Epitopes present on Envelope protein are capable of inducing 
homologous as well as heterologous antibodies. 
 The plasma leakage is  induced by C3a,C5a and several mediators 
leading   to the increased vascular permeability during  the acute febrile 
stage .The plasma leakage is  prominent during “critical period” which 
lasts from 24 hrs before and 24 hours after the day of defervescence of 
fever1. The evidence of plasma leakage includes hemoconcentration, 
hypoproteinemia/hypoalbuminemia, pleural effusion, ascites, threatened 
shock or profound shock7. 
      Vascular permeability in Dengue Haemorrhagic fever is associated 
with increased immune activation as manifested by increased levels of 
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plasma soluble TNF receptor (sTNFR/75) IL-8, IFN-γ, local endothelial 
proliferation of IL-8, RANTES with apoptotic endothelial cell death. 
Immune complex formed by antigen and antibody leads to complement 
activation1. 
The cause of bleeding diathesis in Dengue is complex. It is caused 
by vasculopathy, thrombocytopenia, platelet dysfunction and 
coagulopathy29.Haemorrhagic diathesis is due to a combination of 
cytokine activation and vascular injury. Viral antibodies binding to 
platelets or cross reacting with plasminogen and other clotting factors, 
decreased platelet function and survival leads to mild consumptive 
coagulopathy.10 
The pathogenesis of severe disease is not well understood and 
multiple factors may be implicated. During secondary infection with 
another serotype, the heterologous antibodies increases the viral uptake 
not neutralized and replication takes place in Fc receptor bearing cells 
This phenomenon is  called as  Antibody dependent enhancement 
(ADE)30,31,29,12.This forms the basis of severe dengue infection and  in  
infants with primary infection. ADE- results in high viral load and 
increased inflammatory response which accounts for capillary leak 
syndrome6. From this it is clear that the dengue vaccine must induce 
protection simultaneously to all serotypes32.   
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Dengue haemorrhagic fever is an infrequent but potentially lethal 
form of illness usually due to secondary infection by heterologous 
serotype. The pathophysiology of DHF is multifactorial involving viral 
nature, host genetics, host immunity and previous exposure to the virus29. 
Higher plasma viremia early in the course of infection and consequent T-
cell activation predispose to DHF8. 
In patients with DHF, production of various proinflammatory 
cytokines/chemokines and complement is increased. Genes encoding for 
IL-10, IL-8, IL-1β, IL-32/NK4, IFN-γ, TNF-α, MIP-1β, RANTES, 
CXCL7, CXLI, properdin, and factor D component of complement were 
more strongly expressed in Peripheral blood mononuclear cells of 
patients with DHF than DF5. 
 DHF in primary or secondary dengue is due to the occurrence of 
abnormal immune response involving  production of cytokines or 
activation of T-lymphocytes and disturbance of the hemostatic 
system29.According to Scott B Halstead33 DHF is not significantly 
associated with secondary dengue infection as it can result from a virulent 
dengue virus strain causing primary infection itself. 
        The  mediators   like  C3a,C5a,TNF-α, interleukin (IL)-2, IL-6,IL-
10, IFN–α and histamine  are elevated in DHF than Dengue fever.This 
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indicates enhanced activation of cross reactive T cell which leads to 
increased viral uptake and replication in macrophages and 
monocytes.This is called as  “original antigenic sin”29.  
         Profound T cell activation and death of T cells, during acute dengue 
infection may suppress or delay viral elimination. This further leads to the 
higher viral loads and increased immunopathology found in patients with 
DHF25.   
     Illness after infection with 2 serotypes occurs infrequently and illness 
after 3 infection virtually never. Repeated episodes of DHF have been 
recognized rarely, presumably because of immune factors that promote 
immunopathologic response are outweighed by immune response that 
clear infection.  
Pathologic feature of Dengue in DHF/DSS-  
          Midzonal and hepatocellular necrosis, minimal inflammatory 
response, councilman bodies, microvesicular fatty changes,hypercellular 
and hyperplasia of mononuclear phagocytic cells in lymphoid tissue. 
Atypical lymphocytosis in peripheral blood, widespread infection of 
mononuclear phagocytes and endothelial cells are seen 12.The degree of 
liver dysfunction in dengue infection varies from mild injury with 
elevation of aminotransferases alone to severe injury with jaundice and 
hepatic failure. The severity of dengue infection varies depending upon 
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type of infection and is more in complicated dengue. AST and ALT 
levels are increased in DHF1 
             Malaise and flu like symptoms in Dengue are due to cytokine 
response. Myalgia is due to pathological changes in muscle due to 
moderate perivascular mononuclear infiltrate with lipid 
accumulation. Severe Musculoskeletal pain indicates viral infection of 
bone marrow including mobile macrophages and dendritic cells 
(CD11b/CD18 [Mac-1] positive) and relatively non motile adventitial 
reticular cells (nerve growth factor receptor positive).  
      Local suppression of erythrocytes, myelocytic and thrombocytopenic 
precursors within 4 – 5 days which is reflected in peripheral cytopenia 
resembling a picture of malignancy. Histopathologic examination of skin 
show minor degree of lymphocytic dermal vasculitis and variably viral 
antigen.  
      Thrombocytopenia and hemoconcentration are constant findings in 
DHF.A drop in platelet count below 1lakh is seen from 3rd day to 8th day 
of illness. Hemoconcentration with rise in hematocrit >20% is definitive 
evidence of plasma leakage.WBC count varies ranging from leucopenia 
to leucocytosis which is more common towards the end of febrile phase 
of illness. 
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     Turk cells are transformed lymphocytes.Presence of more than 20 % 
of turk cells in buffy coat smear is a frequent finding of dengue 
hemorrhagic fever 34. 
Immunological Response to Dengue infection: 
The acquired immune reponse following a dengue infection 
consists of the production of IgM and IgG antibodies primarily directed 
against the virus envelope proteins .The immune response differs for 
primary and secondary infection. 
In primary dengue IgM is the first immunoglobulin isotype to 
appear. IgG is detectable in low titre at the end of first week and slowly 
increases. In contrast, in secondary dengue antibody titres rise extremely 
rapidly due to the presence of antibody to the previous infection and these 
antibodies react broadly with other flaviviruses. High levels of IgG are 
detectable even in acute phase and rise dramatically over the proceeding 
2 weeks. IgM levels are significantly lower in secondary infections. 
PAHO says that 80% of all dengue cases have IgM antibody by day 5 of 
illness and 93-99% cases are detectable by 6-10 days and remain 
detectable upto 90 days. The presence of antibodies in dengue is 
protective to the infecting serotype but short lived for heterologous 
serotype. The level of neutralizing antibodies corresponds with protection 
against dengue virus. 
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Clinical features: 
Incubation period of Dengue is 2 to 7 days and is characterized by 
high fever, headache, retro orbital pain, lumbosacral pain, conjunctival 
congestion and facial flushing. Biphasic fever pattern- fever upto 3 rd day 
of onset which subsides and rises again from 5 th to 7 th day. Because of 
regular fluctuations in temperature it is also called as ‘saddle back’ fever. 
Fever is usually associated with severe generalized myalgia and 
arthralgia which gives the name as ‘Breakbone fever’.  Maculopapular 
rash appears on the trunk on 1st /2nd day (non irritating rash) then spreads 
centripetally to the face and limbs but spares palms and soles. 
Generalised lymphadenopathy, cutaneous hyperaesthesia, altered taste 
sensation can occur. 
 Unusual manifestations are neurological, hepatic, renal and isolated 
organ involvement. 
 According to WHO Guidelines Dengue fever, Dengue haemorrhagic 
fever and Dengue shock syndrome are defined as follows: 
Dengue fever: fever of 2-7 days associated with symptoms like 
Arthralgia, myalgia, vomiting, abdominal pain, rash, retro orbital pain, 
 conjunctival congestion, haemorrhagic manifestation,or leucopenia. 
Dengue haemorrhagic fever:  DHF is defined by the presence of above 
symptoms plus thrombocytopenia, evidence of increased vascular 
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permeability (i.e.hemoconcentration, pleural or abdominal effusion, 
hypoalbuminemia or hypoproteinemia). DHF has 4 grades.  
Dengue shock syndrome: Defined by the presence of symptoms of DHF 
with reduced perfusion towards the defervescence and early signs of 
shock manifested as narrowing of pulse pressure or hypotension for age.  
The symptoms of DSS are cold clammy extremities, flushed face, 
diaphoresis, restlessness, irritability and mild epigastric pain12. 
Induction of shock in Dengue is influenced by the following: 
1. Presence of enhancing and non- reacting antibodies. 
2. DHF/DSS is common upto 12 years of age and drops later. 
3. Females are affected more than males. 
4. Race- Caucasians are affected more. 
5. Nutritional status- Malnutrition is said to be protective as they have 
deficient immune response to infection. 
6. Sequence of infection- Serotype 1 followed by Serotype 2 infection is 
more dangerous. 
7. Infecting serotype- Type 2 is apparently more dangerous than other 
serotypes. 
Period of shock is about 1-2 days18 so prompt supportive  management 
and good care with close  monitoring  during this period would prevent 
complications and save the life of the patient . 
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 Apart from the above causes,WHO also defines the high risk group as 
infants and elderly, obesity, Pregnancy , peptic ulcer disease, women 
who have menstrual  / abnormal  vaginal bleeding.Other risks factors 
like  G-6PD deficiency ,thalessemia and hemoglobinopathies ,chronic 
disease like DM, asthma, SHT are also said to be associated.35 
Laboratory Diagnosis: 
Efficient and accurate diagnosis of dengue is of primary importance in 
detection of cases and early treatment. Laboratory diagnostic methods of 
detection of dengue are 
Serological methods 
Viral isolation 
Detection of viral nucleic acid. 
In complete blood count platelet count and the total WBC count would 
be reduced depending upon the type of fever. As the WBC count 
becomes low, platelet counts also becomes  very low  but during the 
recovery stage WBC count rises rapidly than Platelet count .Platelet count  
is usually  reduced more during the DHF and DSS. 
Neutropenia with atypical lymphocytosis resembling malignancy could 
be seen in peripheral smear. Packed cell volume should be estimated as it 
rises in Dengue haemorrhagic fever rapidly.  
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In liver function test –Enzymes like Aspartate aminotransferase and 
Alanine aminotransferase are elevated depending upon the type of injury.  
Serological methods: 
Rapid diagnostic tests: 
  Various commercial kits are available for dengue detection using 
the envelope glycoproteins of dengue for IgM and IgG antibody detection 
and NS1 antibody for antigen detection. 
Lateral flow immunochromatographic test allows detection of both 
antigen and antibody simultaneously with single serum sample,therefore 
differentiation of primary and secondary dengue can be made with single 
sample in contrast to multiple samples required for HAI.  It produces 
results within 15- 20 minutes and it has the advantage of ease of 
performance also. But the sensitivity and specificity of these tests are not 
known and are yet to be evaluated .According to WHO , these RDTs are 
not be used for clinical management  because of  false negativity  that can 
lead to missing of diagnosis and  fatal complications36.  
Enzyme immunosorbent assay (ELISA): 
Antigen detection: 
Enzyme Immunoassays for antigen detection have four steps. An 
antigen specific antibody is attached to a solid phase surface. Patient 
serum that may contain the antigen is added next. An enzyme labeled 
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antibody specific to the antigen (conjugate) is added. Finally substrate is 
added which changes colour in the presence of the enzyme. The amount 
of colour that develops is proportional to the amount of antigen present in 
the patient specimen.  
NS1 protein can be detected by ELISA as soon as first day of fever 
and can be found upto 9 days in serum even when PCR is negative and 
where PCR is not available. It might serve as early prognostic marker for 
severe dengue infections37. 
Antibody detection:  
Immunocapture ELISA: It is designed to detect a specific type of 
antibody such as immunoglobulin M or immunoglobulin G.Antibody 
specific for IgM or IgG is attached to solid phase surface.The Patient 
specimen potentially containing IgM or IgG is added. Specific antigen is 
added. Finally chromogenic substrate is added which in the presence of 
the enzyme changes colour.The amount of colour that develops is 
proportional to the amount of antigen specific IgM or IgG in the patient 
serum. 
Capture ELISA is found to be highly sensitive and is routinely used 
in diagnosis of dengue infections. They are simple to perform and large 
number of samples can be tested at the same time. 
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A.IgM capture: It is the widely used ELISA for detection of 
antibodies.It shows good sensitivity and specificity only when used 5 or 
more days after onset of fever. A positive result indicates recent infection 
but cannot identify the serotype.There are different formats of capture 
ELISA available like capture ultramicro ELISA, dot ELISA, Aubiodot 
IgM capture ELISA and dipstick. Samples like saliva, serum on filter 
paper could also be used. Different commercial kits are available with 
varying sensitivity and specificity38. 
B.IgG capture: This capture ELISA is commonly used for 
classifying cases based on type of infection like primary and secondary 
infection. When used along with IgM the ratio is calculated and according 
to standard criteria it is classified as primary or secondary. In primary 
dengue IgG is detected after 2 weeks and persists for life. In secondary 
dengue IgG antibody to the previous infection rises immediately within 1-
2 days before the appearance of IgM. It is followed by IgM to the present 
infection and IgG after 1week25.  
Other serological methods available for the detection of dengue 
antibodies: 
Neutralisation tests:  These tests are technically demanding and 
time consuming and are performed only in reference laboratories25        
Complement fixation test: One of the classic methods for demonstrating 
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the presence of antibody in a patient’s serum has been the complement 
fixation test. As the procedure is cumbersome, requires highly trained 
personnel and the reagents are thermolabile it is not used for routine 
diagnosis39. 
 Heamagglutination inhibition test: This test can be used for suspected 
DHF/DSS but results are delayed in   time when compared to Capture 
ELISA .Hence it cannot be used for routine diagnostic purposes40. 
 Indirect immunofluorescence test41 
 Dot Blot ELISA42 
Viral isolation:  
Mosquito Cell lines, mammalian cell lines and adult mosquito 
inoculation. 
In acute phase of infection isolation and identification of the virus is the 
only way to diagnose early dengue infection. Serum collected from 
patient is applied to mosquito cell lines .After amplification of virus in 
cell line the serotype is identified using monoclonal antibodies. This 
technique is sensitive only if there is high viremia in the early stages. 
common cell lines used are C6/36(Aedesaegypti), 
AP61(pseudoscutellarius) The CPE on cell lines appears between 1-4 
days post inoculation –cells become round and swollen leading to 
multinucleated giant cells and syncytia formation. 
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In Mammalian cell culture (LLC-MK2) –CPE occurs after 14 days. 
Least sensitive methods are Intra thoracic inoculation of mosquitoes. 
Eventhough  viral culture once considered as ”Goldstandard”, because of 
its lower sensitivity, long time required and applicable only for acute 
samples this procedure has been replaced by molecular diagnosis43. 
Animal inoculation: Intracerebral inoculation of serum into suckling 
mice of 1-2 days old done using tuberculin syringe into the lateral 
hemisphere. After inoculation the mice is observed for sickness daily for 
any sign of abnormal behavior  and if positive it is euthanised, brain 
tissue is harvested and subjected to relevant tests for confirmation. As this 
is a tedious procedure and time consuming, it cannot be applied for 
routine use43. 
Detection of Nucleic acid: RT –PCR provides a rapid and simple method 
for detection of RNA viruses in serum samples and tissue specimens. 
Viral genome is amplified using oligonucleotide primers and the 
amplified product is detected using reverse transcriptase enzyme. 
Recently conventional RT-PCR has been replaced by Real time PCR 
which can be automated. Sensitivity ,Specificity and rapid detection of 
minute quantities of nucleic acid in patient’s serum makes RealTime -
PCR more sensitive with less contamination and easy identification of 
circulating serotype by analyzing the unique sizes of amplicon. Other 
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methods available for nucleic acid detection are NASBA, Hybridization 
probes44. 
 
Differential diagnosis of Dengue fever: Scrub typhus, Leptospirosis, 
Malaria, Chikungunya, Influenza, Measles, Rubella45.These diseases 
could be ruled out by clinical examination and appropriate laboratory 
tests 
Dengue vaccine: More researches have been carried out to develop a 
dengue vaccine that is safe   and   immunogenic against all 4 serotypres. 
Attempts to develop an effective vaccine have been hampered by the lack 
of   understanding of the pathogenesis of disease and absence of suitable 
experimental   model. Dengue vaccine must provide solid and long 
lasting protection against all dengue virus serotypes. Live attenuated 
tetravalent candidate vaccine are in the late stage of development   which 
is produced by serial passage of wild type virus in primary dog kidney 
cells or other cell types46. Sanofi Pasteur has reported successful results 
of phase II trials of tetravalent   recombinant live attenuated vaccine47. 
 Non- recombinant candidate vaccine using structural& non-structural 
purified proteins and   synthetic peptides 13                                           
Recombinant subunit (Escherichia coli, baculovirus, yeast) 13 
 Recombinant subunit vaccine was produced by coating the β domain of 
dengue serotypes 1-4 to the binding protein of  E.coli .Its  efficacy was 
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evaluated in  mice as single or tetravalent vaccine.Neutralising antibody 
titres to each individual serotype was significantly greater than cross 
reactive neutralising titre  compared to tetravalent vaccine 48. 
Recombinant vector13 
Infectious cDNA clone technology has also been exploited for 
development of   dengue vaccine .A chimeric Yellow fever dengue type -
2 vaccine prepared by using recombinant cDNA of a Yellow fever 
vaccine strain as a backbone to which pre membrane and envelope gene 
of DEN-2 were inserted. It is in Phase II-III trial12. 
 DNA vaccine is another novel and promising immunization approach.In 
order to improve the immunogenicity of DEN-2 candidate vaccine 
cytoplasmic region of envelope gene was replaced by lysosome 
associated membrane protein.13.  
Treatment: No specific drugs are available for the treatment of Dengue 
Proper maintenance of fluid balance is the cornerstone of management in 
Dengue. 
 Supportive and symptomatic treatment 
- I.V. Fluids ,Bed rest 
- Parcetamol for control of fever 
- Aspirin and NSAIDS must be avoided.  
31 
 
- Platelet and HCT should be monitored daily beginning on the third 
day of fever. 
- Blood and platelet transfusion if required –depending upon the 
occurrence of bleeding in GI tract but does not correlate with 
platelet count. 
- Early recognition of leakage phase with prompt resuscitation and 
Close monitoring with oxygen, pulse, blood pressure and urine 
output would help to reduce complications and improves the 
treatment outcome.   
Prevention: Neither vaccine nor specific drugs are available .Hence 
prevention by vector control of Aedes aegypti plays a major role in 
Dengue endemic countries. 
Vector control: 
 Mosquitoes that rest indoors are easy to control. Female Aedes aegypti 
are indoor daytime biters. It is difficult to avoid species biting in 
daytime than those species that bite at night. 
Removal or filling of breeding habitats in man made & natural 
containers, burning of organic waste, screen fitting of mosquito proof 
lids to drinking water storage containers, installing piped drinking 
water supply. 
 Safe and effective larvicides to breeding sites. 
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Personal protective equipments for the daytime biting mosquitoes are 
protective clothing like wearing long sleeved clothes,repellents & 
house screening ,indoor space spraying ,mosquito coils, mats, bed nets 
& air conditioning. 
Applying insect repellents to both skin and clothing using permethrin is 
found to be effective. The most effective repellents contain DEET. 
 Biological control 
 Antilarval measures: 
1. Eliminating or changing the breeding place to make it unsuitable 
for development of larvae. 
2. Making the breeding place inaccessible to adult mosquitoes. 
3. Releasing fish/predators that feed on larvae. 
Gambusia affinis /Poecilin reticulate endotoxin producing 
bacteria (Bacillus thuringiensis serotype H-14, Bacillus sphaeria) 
and copepod crustaceans are currently used .These are suitable 
for large containers that are not cleaned regularly as frequent 
cleaning leads to depletion of nutrients available for the larvae.  
4. Applying larvicides wherever necessary. 
 Antiadult measures:  
          1. Epidemic situations- outdoor space spraying with insecticides. 
          2. Insecticidal spray are usually applied to parts of town where        
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             Abundant    breeding sites are   available supporting large    
              Population of Aedes. 
      3. Pyrethrin Knockdown sprays /Organo phosphate sprays can be   
          delivered in microdroplets49,26. 
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MATERIALS AND METHODS 
 
Study design: This is a Prospective study 
Study period: One Year from September 2011 to August 2012.Approval 
from Ethical committee obtained for this study. 
Inclusion criteria: Patients suffering from fever of 1-12 days duration 
with any of these symptoms like myalgia, arthralgia, headache, rash, 
anorexia, nausea, and vomiting, abdominal pain. 
Exclusion criteria:  Patients suffering from other nonspecific fevers 
without clinical features suggestive of dengue fever, Urinary tract 
infections, pneumonia and lung abscess etc. 
Statistical analysis: Statistical analysis of results of this study was done 
using SPSS version 17, p value obtained from chi-square test.  
Sample collection:  About 5 ml of venous blood was drawn from 350  
suspected  patients of dengue fever  after taking informed consent, under 
aseptic precautions in sterile containers .These samples were centrifuged  
at 1500 rpm for 10 minutes & and serum separated .If the  sample was not 
tested immediately it  was stored at -200 c. 
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Methodology 
 
  
The serum samples collected were subjected to Dengue duo 
NS1Ag +Ab combo cassette, NS1 capture ELISA, IgM Capture and IgG 
Capture ELISA in the Department of Microbiology, at Coimbatore 
medical college hospital. 
 
Immunochromatography card test (ICT): 
       
 Dengue duo combo card:   
 
The rapid test is an in-vitro immunochromatographic one step assay to 
detect both dengue virus Nonstructural (NS1) antigen and differential 
IgG/IgM antibodies to dengue virus in serum, plasma or whole blood. 
The left side of Dengue duocard is the NS1 Ag rapid test for qualitative 
determination of antigen. It has a circular well for addition of sample. The 
test device contains a membrane strip precoated with anti-dengue NS1 Ag 
capture on test band region. 
The right side of the card is a solid phase immunochromatographic assay 
for rapid, qualitative and differential detection of IgG and IgM antibodies 
to dengue virus in serum, plasma and whole blood .The card has a square 
well for sample addition, a circular well for buffer and a lateral flow 
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membrane with colloidal gold conjugate   containing recombinant dengue 
antigen and a control. 
Principle of the test: 
The dengue NS1 antigen card can identify dengue virus NS1 
antigen in serum, plasma or whole blood specimens with a high degree of 
sensitivity and specificity. Dengue IgG/IgM rapid test is designed to 
simultaneously detect and differentiate IgG, IgM antibodies to dengue 
virus.This test can also detect all 4 serotypes by using a mixture of 
recombinant dengue envelope proteins. 
When a specimen is added to the sample well anti-dengue IgG  
&IgM antibodies in the specimen will react with recombinant dengue 
envelope proteins –colloidal gold conjugates and  forms a complex of 
antibody-antigen. As this complex migrates along the length of test 
device by capillary action, it will be captured by the relevant anti-human 
IgG and /or anti –human IgM immobilized in 2 test lines across the test 
device and generate a coloured line. 
 
Procedure: 
1. The card was placed on an even surface after being unwrapped 
from the cover. Id no  & date  noted down on the card 
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2. With the dropper provided 10 µl of serum was added to the sample 
well followed by 4 drops of buffer on the right side of the card. 
3. With another dropper provided 100µl of sample was added to the 
antigen well on the left side of the card. 
4. Results were read after 15-20 minutes. 
Results: 
   Antibody   
1. Appearance of bands in all the lines on the antibody card 
2. Appearance of control & “M” line  alone  
3. Appearance of control &”G” line alone. 
4. Appearance of control line alone 
   Antigen:  
 
      Appearance of bands in control area alone  
      Appearance of bands in control and test regions. 
  Interpretation:  
1. Antibody : 
a. Presence of control line alone- test is negative for antibodies. 
b. Presence of all the lines control, M and G – both IgM &IgG 
Positive  -Indicates either late primary or early secondary infection  
c. Presence of control and M line alone- primary dengue 
d. Presence of control and G line alone- secondary or past dengue 
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e. Absences of control line – invalid and test to be repeated.  
2. Antigen :  
a. Presence of bands in both test &control area – positive for NS1 
antigen. 
b. Presence of band in control area alone- negative for antigen 
c. No bands in the result window, it is invalid– test has to be  
repeated. 
Dengue EARLY ELISA 
Principle of the test: NS1  antigen  present in the serum binds to the  
anti-NS1   coated on the microwell strips .The unbound antigen if present 
is removed by  the   washing step.HRP conjugated monoclonal anti-NS1 
antibody is added. A colourless substrate TMB is added which produces 
blue colour .On addition of stop solution phosphoric acid it changes to 
yellow colour.   
Procedure: 
1. 100µl  of diluted sample & controls were added  into the respective 
wells 
2. The plate was Covered &incubated for 1 hour at 370 c 
3. At the end of 1 hour Plate was washed 6 times with diluted  wash 
buffer   
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4. 100µl of Horseradish peroxidase(HRP) conjugate was added into the 
well. 
5.  The plate was Covered & incubated at 370 c for 1 hour. 
6.  Washed 6 times with diluted wash buffer at the end of incubation. 
7. 100µl of Tetramethylbenzidine(TMB) was added into each well 
8. Incubated for 10 mts at Roomtemperature(RT) & observed for blue 
colour 
9. 100µl of stop solution was added & the change of colour noted. 
10. Absorbance value of each well measured at 450 nm with  reference   
filter 600-650nm    spectrophotometrically. 
Calculation:  
     Average absorbance of calibrator triplicate multiplied by the  
     calibration factor 
     Cut off value(COV) = absorbance of calibrator X  cal. Factor 
     Cal .factor=0.57 
     Index value= sample OD/ cutoff value 
     Panbio units= Index value x 10 
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Test validity: 
     Negative absorbance < 0.250 
     COV >1.5 X Negative absorbance. 
     Positive control/ cutoff ratio= 1.1-7.0 
 
Interpretation: 
Index Panbiounits Result 
<0.9 < 9 Negative 
0.9-1.1 9-11 Equivocal 
>1.1 > 11 Positive 
 
Dengue IgM capture ELISA: 
Principle of the test: 
 Serum antibodies of the IgM class, when present, combine with 
anti-human IgM antibodies coated on the polystyrene surface of the 
microwell test strips (assay plate). The diluted recombinant antigen is 
mixed with equal volume of horseradish peroxidase (HRP) conjugated 
monoclonal antibody (MAb) allowing the formation of antigen-MAb 
complexes.  Addition of complexed antigen-MAb complexes following 
washing will bind to the serum dengue-specific IgM antibodies. After 
incubation a colourless substrate tetramethylbenzidine/hydrogen peroxide 
41 
 
(TMB Chromogen) is added. The substrate is hydrolysed by HRP if 
present, and the chromogen turns blue. After stopping the reaction with 
acid, the TMB turns yellow. Colour development is indicative of the 
presence of anti-dengue IgG antibodies in the test sample. 
Procedure: 
All the kit reagents were brought to room temperature before start of the 
test. 
ELISA Procedure: 
1. Dispensed 100µl of diluted patient serum, positive and negative      
control, calibrator in triplicate added to their respective wells in the 
microtiter plate. 
2. The microtiter plate was covered and incubated at 370 c for 1 hour 
3. Antigen was diluted in 1/250 with antigen diluent i.e 10µl of antigen in  
    2.5ml of antigen diluent.    
4. Required amount of diluted antigen is mixed with equal volume of  
    Monoclonal antibody tracer and incubated at room temperature until  
    required. 
5. The plate was washed 6 times with diluted wash buffer at the end of  
    incubation. 
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6. Added 100µl of antigen antibody mixture to all the wells  
7. The plate was covered and incubated at 370 c for 1 hour. 
8. At the end of incubation, plate was washed 6 times with diluted wash 
buffer 
9. Added 100µl of TMB substrate  to the wells and incubated in the dark    
for 10  minutes. 
10. 100µl of stop solution added to all the wells. 
11. Absorbance value of each well measured spectophotometrically at     
      450nm wavelength with reference filter of 600-650nm. 
Calculation: 
• Average absorbance of the triplicate of the calibrator multiplied by 
the calibration factor. This is the cutoff-value. 
• An index value is calculated by dividing  the sample absorbance by 
the cut-off value 
Index value= sample absorbance/ cut-off value 
Panbio units= Indexvalue x 10 
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Test validity: 
Cutoff value>1.5x neg.absorbance 
Calibrator mean>negative absorbance 
Positive control/cutoff value=1.1-8 
Negative control<0.40 
Calibration factor=0.99 
 Interpretation of results: 
INDEX PANBIOUNITS RESULT 
0.9 < 9 Negative 
0.9-1.1 9-11 Equivocal 
>1.1 >11 Positive 
 
Dengue IgG capture ELISA 
Principle of the test: Serum antibodies of the IgG class, when present, 
combine with anti-human IgG antibodies coated on the polystyrene 
surface of the microwell test strips (assay plate). An equal volume of 
horseradish peroxidase (HRP) conjugated monoclonal antibody (MAb) is 
added to the diluted antigen, allowing the formation of antigen-MAb 
complexes. Residual serum is removed from the assay plate by washing, 
and complexed antigen-MAb complexes added then bind to the serum 
dengue-specific IgG antibodies. After incubation   a colourless substrate 
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added to the washed wells and was followed by 
tetramethylbenzidine/hydrogen peroxide (TMB Chromogen) addition. 
The substrate is hydrolysed by HRP if present, and the chromogen turns 
blue. After stopping the reaction with acid, the TMB turns yellow, Colour 
development is indicative of the presence of anti-dengue IgG antibodies 
in the test sample. 
Preprocedure preparation: 
All the kit reagents were brought to room temperature before the 
commencement of the procedure. 
Procedure: 
Antigen diluted 1/250 using antigen diluent i.e. 10µl antigen mixed with 
2.5ml  of antigen diluent .About 0.5ml of diluted antigen is required per 
strip. 
 Equal volume of diluted antigen   mixed with monoclonal antibody tracer   
solution. This is incubated   at room temperature for 1 hour. 
1. Dispensed 100 µl of diluted sample, positive control, negative 
control and calibrators in   triplicate   to the respective wells 
2. The plate was covered and Incubated at 37 0c for 1 hour. 
3. Plate was washed 6 times with diluted wash buffer at the end of  
incubation  
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4. Added 100 µl of Ag –MAb tracer solution to all the wells at the 
end of incubation 
5. Plate was covered and Incubated at 370c for I hour. 
6. Washed 6 times with wash buffer at the end of incubation. 
7. Added 100 µl of TMB was to all the wells. 
8. Incubated at dark for 10 minutes. 
9. Added 100µl of stop solution   to all the wells 
10. Absorbance value of each well measured at 450 nm wavelength 
with 600-650 nm reference filter spectophotometrically. 
Calculation: 
1. The average absorbance of the triplicate of the calibrator is 
multiplied by the calibration   factor. This is the cut-off value. 
2. Index value is calculated by dividing the sample absorbance by the 
cut- off value. 
Test validity: 
Cutoff value= 1.5x neg.absorbance 
Calibrator mean >negative absorbance 
Positive control/Cutoff value= 1.1-6.0 
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Negative control<.350 
Calibration factor=1 
Index value= Sample absorbance / cutoff value 
Panbio units= index value x 10 
Interpretation of results: 
INDEX PANBIOUNITS RESULT 
<1.8 <18 Negative 
1.8-2.2 18-22 Equivocal 
>2.2 >22 Positive 
 
The haematological and biochemical profile of dengue positives were 
estimated in the respective Departments and results were collected. 
 Dengue Duo Combo Card Kit 
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RESULTS 
During  the study period of one  year Blood was collected  from 350  
clinically suspected  dengue cases .The samples were subjected to Dengue 
serology for both NS1 antigen and IgM,IgG antibody detection by ELISA 
and ICT.The 107 seropositive   samples by ELISA were  further analysed for 
demographic ,clinical and laboratory data including  haematological and 
biochemical profile. The Statistical analysis of results of this study was done 
using SPSS version 17.p value obtained from pearson chi-square test. 
 In this study the seropositivity of dengue was 30 %( Ref Table 1). 
The age of the seropositives ranged from 0-72 years and the 
commonest age group affected in this study was 0-10years 45 (42%) 
followed by 11-20 years 27 (25.2%), 21-30years 16 (14.9%), 31-40years 12 
(11.2%) .The incidence was less in the age group of 41-50years and 51-60 
years each constituting about 2 (1.8%) and >60years 3 (2.8%). (Ref Table2) 
The male: female ratio was 1.6:1 in this study with males   67 (62.3%) and 
females 40(37.7%)  (Ref Table 2). 
The incidence of dengue cases in this study month wise were 
September   2 (16.6%), October 0 (0%) November 5 (21.7%), December 12 
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(25.5%), January 13 (31.7%), February 2 (13.3%), March 1 (4.3%), April 4 
(23.5%), May 13 (26.5%), June 41 (50.6%) and July13 (52%) and August 1 
(12.5%). (Ref Table 3). 
The common clinical symptom was fever 107 (100%), followed by 
headache 65(60.7%),Myalgia 41(38.3%),Arthralgia 32 (29.9%),Abdominal 
pain 30 (28.03%),vomiting 26 (24.2%) ,Oliguria and Rash was observed in 5 
cases(4.6%).( Ref Table 4) 
Melena 11(10.2%) was the commonest bleeding manifestation 
followed by bleeding gums 5 (4.6%),Hemetemesis 4 (3.7%) and Epistaxis 3 
(2.8%) (Ref Table 4) 
The positive cases were classified as Dengue fever 52(48.5%), 
Dengue haemorrhagic fever 53(49.5%) and Dengue shock syndrome 2(2%) 
according to WHO guidelines. ( Ref Table 5). 
In this study thrombocytopenia was associated with majority of 
Dengue positive cases .The common range was 51,000-1lakh44 (41.1%) 
followed by 21000-40,000 30(28.03%),<20,000 13(12.14%),41,000-50,000 
10(9.34%)and>1lakh 10(9.34%).Amongthrombocytopenia<1lakh 43(82.6%) 
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were associated with denguefever,52 (98%) with Dengue haemorrhagic 
fever and 2 (100%)with Dengue shock syndrome. (Ref Table 6 & 9). 
In this study leucopenia (count <4000) was observed in 79(73.8%) 
dengue positive cases .Out of 52 Dengue fever cases 37 had 
leucopenia(71.1%), out of 53 DHF 40 had leucopenia(75.4%) and out of 2 
DSS both had leucopenia(100%). Eight cases (7.5%)had WBC count of 
4000-5000, 7 were in 5100-6000(6.5%) range, 6 were in 6100-7000range 
and 7 cases had count >7000(6.5%). (Ref Table 7&9). 
Elevated Haematocrit > 45% was observed in 33(30.8%) cases. 
Among them 5(9.6%) were associated with Dengue fever and 26(49.05%)   
with Dengue haemorrhagic fever and 2(100%) with Dengue shock 
syndrome.HCT level in other cases were 35-44 in 30(28.03%) cases, 25-34 
in 34(31.7%) and <25in 10 case (9.3%) . (Ref Table 8&9) 
Liver parameters like ALT and AST were raised in 24(22.4%) and 
28(26.1%) cases respectively. Among ALT elevated cases 8 (15.3%) were 
associated with Dengue fever, 14(26.4%) were associated with Dengue 
haemorrhagic fever and 2(100%) were associated with Dengue shock 
syndrome. Among AST elevated cases10 (19.2%) were associated with 
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Dengue fever, 16(30.1%) were associated with Dengue haemorrhagic fever 
and 2(100%) were associated with Dengue shock syndrome. (Ref Table 10) 
In Ultrasonogram (USG) Gallbladder thickening 31(28.9%) was observed in 
majority of Dengue positive cases followed by pleural effusion 16 (14.9%), 
ascites 9 (8.4%) and hepatomegaly 7(6.5%). Among GB thickening 5 (9.6%) 
were associated with Dengue fever, 24 (45.2%) with Dengue haemorrhagic 
fever, 2(100%) with Dengue shock syndrome .Pleural effusion of 14(26.4%) 
were associated with Dengue haemorrhagic fever and 2(100%) were 
associated with Dengue shock syndrome and nil case in Dengue fever. 
Ascites of 7(13.2%) were associated with Dengue haemorrhagic fever, 
2(100%) with Dengue shock syndrome and nil case in Dengue fever.  
Hepatomegaly was associated with dengue fever 5 (9.6%) and Dengue 
haemorrhagic fever 2(3.7%) and nil association with Dengue shock 
syndrome.USG was normal in 30(28.03%) cases which was 25 (48%) in 
Dengue fever and 5(9.4%) in Dengue haemorrhagic fever.USG was not 
available for 17 cases of Dengue fever and 1case in Dengue haemorrhagic 
fever.(Ref Table 11) 
Seropositives were categorised as Primary 48(44.9%) and secondary 
dengue 59(55.1%)with ratio0.8:1 based on ELISA .The serological markers 
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included for primary dengue were NS1 alone positive ,NS1 with IgM 
positive, IgM alone positive and IgM&IgG positive with ratio >150. The 
serological markers  and their combination  included  for secondary dengue 
were IgG positive with thrombocytopenia, NS1 & IgGpositive,NS1 ,IgM & 
IgG positive and IgM & IgG positive with ratio <150 .(Ref  Table 12) 
Based on duration of fever ,primary dengue  cases with above  
mentioned markers   were split into 1-5 days(37),6-10 days(10) and >10 
days(1). 
In primary Dengue(PD) NS1 alone showed  positivity of  27(56.25%), 
NS1 & IgM  showed positivity  of  8(16.6%) , IgM  alone showed positivity 
of  9(18.75%), IgM & IgG +ve with ratio >1  showed positivity  of 
4(8.33%). 
  In 1-5 days period NS1alone showed positivity of 27(72.9%) followed 
by NS1 &IgM positivity of 8(21.6%) and IgM, alone positive of 2(5.4%). In 
6-10 days duration IgM alone showed  positivity  of 70% followed by IgM 
&IgG positive with ratio >1positivity of 3(30%). NS1 and NS1 with IgM 
showed nil positivity. In >10 days IgM & IgG  positive with ratio >1 alone 
had positivity of 100% ,others were nil during this period. With  
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p value<0.001 it was found to be statistically significant. (Ref Table 13) 
Similarly  in secondary dengue(SD)  IgG positive  with thrombocytopenia 
showed positivity of 6(10.1%)  , NS1 & IgG of  1(1.6%) , NS1,IgM &IgG  
of 14(23.7%), IgM &IgG positive with  ratio <1  of 38(64.4%) . 
In 1-5 days of secondary dengue  NS1,IgM&IgG 11(47.8%) showed 
higher positivity followed by IgM & IgG positive with  ratio <1 6(26.08%), 
IgG positive  with thrombocytopenia  were 5(21.7%),NS1&IgG positive 
1(4.3%). 
In 6-10 days IgM &IgG positive with ratio <1 showed  positivity of  
22(84.6%) followed by NS1,IgM,IgG positivity  of 3(11.5%)and IgG 
positive  with thrombocytopenia1(3.8%). In > 10 days duration IgM &IgG 
positive with ratio<1 showed higher positivity of 10(100%).Others showed 
nil positivity. With p value<0.001 it was found to be statistically 
significant.(Ref Table 14) 
Case detection by ICT and ELISA showed 26.2% positivity for ICT 
and 30.5% positivity for ELISA. (Ref Table 15) 
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Detection of serological markers like NS1, IgM and IgG by ICT and ELISA 
showed positivity of 36(10.2%), 62(17.7%), 54(15.4%) by ICT and 
50(14.2%), 73(20.8%), 65(18.2%) respectively by ELISA (Ref Table 15a). 
Using ELISA as Reference assay, Sensitivity, Specificity, NPV and 
PPV of the ICT were calculated for NS1 which showed 68%, 99.3%, 94.4%, 
and 85.7% respectively. With p value of <0.001 it was  found to be 
statistically significant.(Ref Table 16) 
Similarly for IgM the ICT showed sensitivity, specificity, PPV, NPV   
of 80.8%, 98.9%, 95.1%, and 95.1% respectively. With p value<0.05 it was 
found to be statistically significant.(Ref Table 17). 
Sensitivity, Specificity, PPV, and NPV of IgG in ICT was 81.3%, 
98.9%, 94.1%, 96.32% respectively. With p value<0.001it was found to be 
statistically significant. (Ref Table 18) 
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Tables 
. 
Table 1 
Seropositivity of Dengue  
Total No. of 
Suspected fever 
Cases 
Total No. of  positive 
cases 
Percentage 
350 107 30.5% 
 
 
 
Table 2 
Age and Sex Wise Distribution of Dengue positive cases 
S.No. Age Group 
 
Male Female Total 
1. 0-10 Yrs 26(24.2%) 19(17.7%) 45(42%) 
2. 11-20 Yrs 18(16.8%) 09(8.4%) 27(25.2%) 
3. 21-30 Yrs 10(9.3%) 06(5.6%) 16(14.9%) 
4. 31-40 Yrs 10(9.3%) 02(2.0%) 12(11.2%) 
5. 41-50 Yrs 01(0.9%) 01(1%) 02(1.8%) 
6. 51-60 Yrs - 02 (2.0%) 02(1.8%) 
7. >60 Yrs 02(1.8%) 01(1.0%) 03(2.8%) 
Total 67(62.3%) 40(37.7%) 107(100%) 
                              Male: Female ratio 1.6:1 
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                                                       Table 3 
Seasonal Distribution of Dengue positive Cases 
Month 
2011-2012 
Total no of cases 
350 
No of Positives 
107 
Percentage  
% 
September 
 
 
12 2 16.6 
October 
 
9 0 0 
November 
 
23 5 21.7 
December 
 
47 12 25.5 
January 
 
41 13 31.7 
February 
 
15 2 13.3 
March 
 
23 1 4.3 
April 
 
17 4 23.5 
May 
 
49 13 26.5 
June 
 
81 41 50.6 
July 
 
25 13 52 
August 
 
 
8 1 12.5 
 
chi square test =30.7, p value<.001(significant) 
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Table 4 
Clinical Presentation of Dengue positive cases  
Symptom No. of Patients Percentage 
Fever 107 100% 
Headache 65 60.7% 
Myalgia 41 38.3% 
Arthralgia 32 29.9% 
Abdominal Pain 30 28.03% 
Vomiting 26 24.2% 
Melena 11 10.2% 
Oliguria 5 4.6% 
Bleeding gums 5 4.6% 
Rash 5 4.6% 
Hemetemesis 4 3.7% 
Epistaxis 3 2.8% 
              
 
Table 5 
Clinical Classification based on WHO Guidelines51 
Category No. of Positive 
Cases 
Percentage 
Dengue Fever 52 48.5% 
Dengue Hemorrhagic 
Fever 
53 49.5% 
Dengue Shock Syndrome 2 2% 
Total 107 100% 
        
chi -square test =47.68, p<0.001(significant) 
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Table 6 
Platelet Count in Dengue positive cases (n = 107) 
Platelet Count 
 
Total  cases Percentage 
% 
<20,000 13 12.14 
21,000 – 40,000 30 28.03 
41,000 – 50,000 10 9.34 
51,000 – 1 lakh 44 41.12 
>1 Lakhs 10 9.34 
Total 107 100 
 
chi-square test=42.766, pvalue<0 .001(significant) 
 
 
 
Table 7 
WBC Count of Dengue positive cases (n = 107) 
WBC Count 
 
Total  cases Percentage 
% 
< 4000 79 73.8 
4000 – 5000 8 7.5 
5100 – 6000 7 6.5 
6100 – 7000 6 5.6 
>7000 7 6.5 
Total 107 100 
 
chi-square test=42.7, p value<0.001(significant) 
 
 
58 
 
 
Table 8 
Level of HCT in Dengue positive cases (n = 107) 
HCT 
 
 Total  cases Percentage 
% 
>45 33 30.8 
35-44 30 28.03 
25-34 34 31.7 
<25 10 9.3 
Total 107 100 
 
chi square test= 42.7, p value <0.001 (significant) 
 
 
                                                        Table 9 
      Association of platelet, Haematocrit and WBC with Dengue positives     
                                                      
Category  
Platelet count  
<  1  lakh(97) 
Haematocrit 
>45(33) 
WBC count 
<4000(79)  
Dengue fever(52) 43(82.6%) 5(9.6%) 37(71.1%) 
 
Dengue 
hamorrhagic 
fever(53) 
52(98.1%) 26(49.05%) 40(75.4%) 
Dengue shock 
syndrome(2) 
 
2(100%) 2(100%)  2(100%) 
 
Total  97 33 79 
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Table 10 
                    Association of ALT and AST in Dengue positive cases  
Category ALT>40(24)   AST>40(28) 
Dengue 
fever(52) 
8(15.3%) 10(19.2%) 
Dengue 
haemorraghic 
fever(53) 
14(26.4%) 16(30.1%) 
Dengue shock 
syndrome(2) 
2(100%) 2(100%) 
Total 24(22.4%) 28(26.1%) 
   
   chi-square test=12.1, pvalue <0.05(significant) 
 
 
Table 11 
USG Findings in Dengue positive cases. 
Category Normal 
%  
GB 
thickening
% 
Pleural 
effusion 
% 
Ascites 
% 
Hepatomegaly 
% 
Dengue 
fever(52) 
25(48) 5(9.6) 0 0 5(9.6) 
Dengue 
haemorraghic 
fever (53) 
5(9.4) 24(45.2) 14(26.4) 7(13.2) 2(3.7) 
Dengue shock 
syndrome(2) 
0 2(100) 2(100) 2(100) 0 
Total  30(28.03 ) 31(28.9) 16(14.9) 9(8.4) 7(6.5) 
. 
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Table 12 
Serological Categorisation of Dengue positives based on ELISA   
Category No. of Positive 
Cases 
Percentage Ratio 
 
0.8:1 
 
 
Primary Dengue  48 44.9% 
Secondary Dengue 59 55.1% 
 
 
                                                     Table 13 
    Primary dengue based on duration of fever &serological markers                   
   
Fever duration NS1 
positive 
 
NS1&IgM 
Positive 
IgM alone 
Positive 
IgM &IgG+ve 
withRatio >1 
 
1-5 Days  
(37) 
27 
(72.9%) 
8 
(21.6%) 
2 
(5.4%) 
 
0 
(0%) 
6–10 Days 
(10) 
0 
(0.0%) 
0 
(0.0%) 
 
7 
(70%) 
3 
(30%) 
> 10 days 
(1) 
0 
(0.0%) 
0 
(0.0%) 
 
0 
(0.0%) 
 
1 
(100%) 
Total 
(48) 
27 
(56.25%) 
8 
(16.6%) 
9 
(18.75%) 
4 
(8.33%) 
 
chi-square test=47.07, p value<0.001(significant) 
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Table 14 
 Secondary Dengue based on duration of fever and serological markers 
Fever 
duration 
IgG+thrombo     
cytopenia 
NS1 &IgG 
Positive 
NS1,IgM&IgG 
Positive 
IgM&IgG+ve 
with Ratio <1 
1-5 Days 
(23) 
5 
(21.7%) 
1 
(4.3%) 
11 
(47.8%) 
6 
(26.08%) 
6 – 10 Days 
(26) 
1 
(3.8%) 
0 
(0.0%) 
3 
(11.5%) 
22 
(84.6%) 
> 10 Days 
(10) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
10 
(100%) 
Total 
(59) 
6 
(10.1%) 
1 
(1.6%) 
14 
(23.7%) 
38 
(64.4%) 
 
chi-square test= 25.12, P value<0.001(significant) 
                                                         
 
        
                                                  Table 15 
                              Case detection by ICT and ELISA 
Test No. of Suspected 
Cases 
No. of Positive 
Cases 
Percentage 
ICT 350 92 26.2% 
ELISA  350 107 30.5% 
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Table 15(a) 
                            Detection of NS1, IgM, IgG by ICT and ELISA  
Test  No of 
suspected 
cases 
ICT ELISA 
NS1 350 36(10.2%) 50(14.2%) 
IgM 350 62(17.7%) 73(20.8%) 
IgG 350 54(15.4%) 65(18.2%) 
 
                                                   
 
Table 16 
   Cross tabulation of ICT and ELISA for NS1 
ICT ELISA Total 
Positive Negative 
Positive 34 2 36 
Negative 16 298 314 
Total 50 300 350 
 
              Sensitivity 68%, Specificity 99.3%, PPV 94.4%, NPV 85.7% 
chi-square test =46.36, p value<0.001(significant) 
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Table 17 
Cross tabulation of ICT and ELISA for IgM 
ICT ELISA Total 
Positive Negative 
Positive 59 3 62 
Negative 14 274 288 
Total 73 277 350 
 
             Sensitivity 80.8%, Specificity98.9%, PPV95.1%, NPV 95.1%  
chi-square test =5.1, p value<0.05(significant) 
 
 
Table 18 
Cross tabulation of ICT and ELISA for IgG  
ICT ELISA Total 
Positive Negative 
Positive 51 3 54 
Negative 14 282 296 
Total 65 285 350 
 
         Sensitivity 81.3%, Specificity 98.9%, PPV 94.1%, NPV 96.32%  
chi-square test=41.3, p value< 0.001(significant)
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Clinical Classification based on WHO Guidelines 
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Chart 11 
Sensitivity, Specificity, PPV & NPV of ICT for NS1,IgM,IgG 
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DISCUSSION 
 
In order to provide timely information for the management of patients 
with acute dengue and effectively control dengue outbreaks, it is important 
to establish an accurate confirmation of acute dengue infection during the 
first few days of clinical symptoms. 
For a long time, detection of dengue specific IgM/IgG has been the main 
stay of diagnosis of Dengue infection. The Dengue specific IgM antibodies 
begin to appear only around fifth day of primary infection. The New 
parameter called NS1 now available can be detected from the first day of 
illness. Dengue NS1 is detected in the blood circulation as early as viral 
RNA detected in PCR. 
In this study the seropositivity   of dengue infection was 30% .In a study by 
Halstead et al 52 1969, Bangkok 29% of febrile illness was associated with 
dengue virus infection similar to this study.   
In a study by Chakravarti A et al53 2011, New Delhi conducted on 145 
samples noted seropositivity of 60.7% which is higher to this study.      
In this study 62.3% of the affected populations were males and 37.7% were 
females. The following studies were found to coincide with this study Aisha 
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sajid, Asim akram, Mubashir Ahmed54 2012, Syed Irfan ahmed et al55 
2010 Fasalabad and Kurukumbi et al21 2001.  
In contrast to this study females were affected more than males in a study by 
Murray smith and Skelly C 56 Queensland. But Susan shepherd et al 57 in 
a study conducted at Pennisylvania showed that dengue infection can occur 
irrespective of sex. 
In this study Male: female ratio was 1.6:1 and this is due to males being 
engaged in outdoor activities and due to their dressing culture when 
compared to females which increases the exposure to mosquito bites. The 
studies by Eng Eong Ooi58 2001 Singapore, Shrivastava et al59 2011 and 
Rajoo Singh Chhina et al 60 2008 Punjab had similar M: F ratio. 
In this study   the commonest age group affected was 0-10 years (42.05%) in 
both sexes. Increased incidence of infection in 0-10 years in this study is due 
to increased mosquito bite exposure in the school premises during the day 
time. The study by Shah GS et al61  Kathmandu    revealed  that the 
commonest age group affected in their study was  from 8months to 14 years 
and  Malavige et al 45 2004 Srilanka study showed age range from 1 month 
to 12 years which is similar to this study. 
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In a study by Anita chakravarti et al 62 conducted at New Delhi the age 
group commonly affected was 26-30 years which is in contrast to this study.  
In this study incidence of dengue cases were more during the months of  
November& December 2011 and January ,May , June, July of 2012 . 
Increase in the incidence of Dengue cases occur usually during rainfall63. 
Tamilnadu receives rainfall from October to November followed by post 
monsoon period of  December & January. The cause for the incidence of 
cases   during the above months like May, June and July in this study is that 
the eggs can survive even in stored waters in the absence of rainfall. 
According to NVBCDP25 2007 every year there is an upsurge in the cases of 
Dengue /DHF from July to November. Ekta gupta et al 64 2006 in their 3 
year study had shown an increase in incidence during Post monsoon period 
(September – November). 
A study by Louise Kelly –hope Mandeleine C.Thomson65 2008 in their 
Study revealed that a climatic change has a role in the transmission of 
Dengue. Umesh Isalkar66 , TNN 2009 said that whether changes cause 
atypical viral fever. 
In this study  the commonest symptom  was  fever100% followed by 
headache 60.7%, Myalgia 38.3%, arthralgia 29.9% ,abdominal pain 28.3% 
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,vomiting 24.2% ,oliguria &,rash 4.6% . Saadiah sulaiman et al 671999 in 
their study had fever of 100% followed by headache (80.9%) arthralgia 
(74%), myalgia (70%), rash (4.6%) and vomiting (62.7%) similar to this 
study. Jonathen et al68 2010 in their study had fever (72%) as most 
common symptom followed by epistaxis, abdominal pain and rashes.    
 Rahman et al69 2002 in their study had headache (90%) as predominant 
symptom followed by myalgia / arthralgia (85%) and vomiting (64%). 
In this study Dengue positive cases were classified according to WHO 
guidelines. It showed 48.5% Dengue fever, 49.5% Dengue haemorrhagic 
fever and 2% Dengue shock syndrome.  In this study DHF is found to be 
high because of increased incidence of infection in children. Because of the 
increased surface area of the blood vessel per unit volume of skeletal muscle 
and the immature blood vessel leading to increased vascular permeability, 
DHF is common in children. Even though Dengue haemorrhagic fever was 
high in this study and is said to be a complication of secondary dengue, DSS 
was comparatively less   because of the eminent care and management given 
to the diagnosed cases in the respective wards.  
In a study by S Kalyanarooj et al70 1997 Thailand, conducted on 60 
seropositives showed 53% (32) Dengue fever, 47% (28) Dengue 
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haemorrhagic fever and Dengue shock syndrome. According to David 
W.Vaughn and Sharone Green71 fatality rate is decreased in DHF /DSS 
cases those who are hospitalised and treated promptly.  
In this study thrombocytopenia   was observed in 90% of the positive cases   
the common range was between 51,000-1 lakh followed by 20,000- 40,000. 
Thrombocytopenia is due to decreased platelet production in Dengue fever 
and increased peripheral destruction in DHF. RD Kulkarni et al 62011 
Karnataka, in their study had thrombocytopenia associated with majority of 
dengue positive cases than dengue negative cases similar to this study. In a 
study by Chandrakanta et al72 2008 revealed 60% of thrombocytopenia < 
1lakh. 
Karande et al73 2005 revealed that arthralgia and thrombocytopenia if 
present in a child increases the chance of the child to be Dengue positive. 
But a study by Col Banerjee et al74 revealed that thrombocytopenia may not 
always be a feature of Dengue.  
In this study leucopenia was observed   in 79/107(73.8%) of dengue positive 
cases. Out of 79, 37 were associated with dengue fever, 40 were associated 
with Dengue haemorrhagic fever, 2 were associated with Dengue shock 
syndrome.The association of leucopenia with Dengue fever,DHF and DSS is 
69 
 
71.1%,75.4% and 100% respectively(Table 9). Neutrophil adhesion to 
dengue infected endothelial cell is one of the causes for leucopenia. 
 Kalyanarooj et al 70 1997 has stated that leucopenia in Dengue  is due to 
bone marrow suppression.In a study by Somachai insiripong MD75 2010 
revealed that  leucopenia in DHF is multifactorial .  
In this study elevated Heamatocrit (>45%) was observed in 33 patients, 5 
were associated with dengue fever, 26 were associated with Dengue 
haemorraghic fever and 2 were associated with Dengue shock syndrome. 
The association of elevated HCT with DF, DHF and DSS are 9.6%, 49.05% 
and 100% respectively. Rise in haematocrit is due to increased vascular 
permeability and plasma leakage in DHF /DSS. Malavige et al 762007 in 
their study have considered hemoconcentration when the packed cell volume 
was >45 in children. 
In this study liver enzymes like AST (Aspartate aminotransferase)) and ALT 
(Alanine aminotransferase) were elevated in 28 and 24 patients respectively. 
Among ALT and AST rise, >40units majority were associated with DHF 
and DSS.  Rajoo Singh Chhina et al 60, Punjab in their study had 
significant rise of AST (97%) and ALT (93%) in DHF/DSS as compared to 
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DF. They also concluded that raised AST can be an early indicator of 
dengue infection. 
In secondary dengue causing liver damage AST will be elevated more than 
ALT which is due to the release of AST from damaged monocytes of dengue 
infection and due to release of AST from skeletal muscles due to myalgia.  
 In this study, the Ultrasound findings showed more of Gall bladder 
thickening followed by pleural effusion, ascites and hepatomegaly . Gall 
bladder thickening is due to increased vascular permeability where the fluid 
tends to collect in between the layers increasing the thickness of the Gall 
bladder which occurs in Dengue haemorrhagic fever and Dengue shock 
syndrome. Similarly the fluid collects in pleural and peritoneal cavity. 
In the study conducted by Bala subramanian et al 772006 ultrasonography 
was found to be superior to radiography in detecting pleural effusion. In the 
study by Kumar et al78 2010 Karnataka, pleural effusion was noted in 4.29 
% (20) of 466 patients which is less than this study. In this study by 
Zulkarnain 79 2004 revealed 29.8% of Gall bladder edema which is higher 
than this study.  
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In this study the incidence of Primary dengue was 48(44.8%) and Secondary 
Dengue was 59(55.1%) in the proportion of 0.8:1. In a study by Jonathan G 
et al68 2010 secondary dengue (81%) was more than primary dengue which 
is similar to this study. In a study by Neeraja M et al22, Hyderabad showed 
72.5% of secondary dengue conducted on 211patients which is similar to 
this study.  
 In 48 samples of  primary dengue  NS1 showed higher positivity (56.25%) 
followed by IgM alone positivity of 18.75% , NS1 &IgM positivity of 
16.6% , and IgM & IgG positive with  ratio >1of 8.33%.During the primary  
infection ,NS1 gets secreted  out from virus infected cells which indicates 
underlying viremia and pathogenesis of infection. As there are low antibody 
titres in primary dengue, the NS1 protein can be estimated more in serum 
during the acute period.  So NS1 detection can be used as a stand alone test    
for Primary dengue in cases when IgM is not detectable and where PCR is 
not available.  
During the acute period of 1-5 days in primary dengue , NS1 detection 
(72.9%) had higher positivity  followed by NS1 & IgM(21.6%) and IgM 
alone positive  of  2(5.4%). As IgM antibodies tends to appear after 4-5 days 
of infection and as many patients in this study presented within 5 days, the 
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sensitivity of NS1 &IgM ,IgM alone positive in primary dengue were less 
when  compared to NS1 positivity alone. Hence when IgM ELISA is 
negative in the acute period, NS1 ELISA should be done for diagnosis which 
significantly improves the detection rate without the requirement of paired 
serum to demonstrate the rise in titre of antibodies. In a study by 
Chakravarti A, Kumar A, Malik S53 2011New Delhi conducted on 145 
acute serum samples NS1 ELISA showed a positivity rate of 65.9% and 
MAC-ELISA showed 60.2% positivity in the acute period. Veasna duong et 
al9 study also showed NS1 positivity to be higher in first 3 days. 
Minipritam singh et al80 and Chua KB et al 812011 studies revealed that 
NS1 antigen capture ELISA was more sensitive than RT-PCR and viral 
isolation. 
During the early convalescent period of 6-10 days in primary dengue, IgM 
showed higher positivity (70%) than other serological markers. This is due 
to the appearance of IgM antibodies after 4th day of illness and is the first 
antibody to appear following Dengue infection. IgM antibody gradually 
increases towards end of first week and it persists for 3 months thereafter. 
The virus may be at undetectable levels in this period as they tend to be in 
complex with IgM antibody. Hence NS1 positivity was less during this 
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period. IgM and IgG combination also showed less positivity (30%) during 
this period as anti dengue IgG is detectable only at low titer during this 
period as it appears still later.  In a study by S Datta and Wattal 82 IgM 
detection by MAC ELISA showed 93.6% positivity in early convalescent 
period.  
In more than 10 days duration, IgM &IgG positive with ratio > 1 showed 
higher positivity (100%) as IgG antibodies would have appeared during this 
period which increases further in the proceeding weeks and persists lifelong 
thereafter. 
In this study, in secondary dengue, IgM and IgG positive with ratio <1 
showed higher positivity (64.4%) than other parameters followed by NS1, 
IgM and IgG combination (23.7%). As the antibody titres rise extremely 
rapidly, IgM and IgG are detected more in secondary dengue. 
During the acute period of 1-5 days in secondary dengue NS1,  IgM and IgG 
combination showed higher positivity11(47.8%) than IgM & IgG 
combination 6 (26.08%),NS1& IgG 1(4.3%) and IgG alone positive  with 
thrombocytopenia 5(21.7%).The NS1 antigen  has reduced sensitivity in 
secondary dengue   because it is sequestered in immune complexes and that 
target epitopes are not accessible to  the plate bound  mAb in NS1 ELISA. 
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High levels of  IgG are detectable even in acute phase  of secondary dengue 
due to previous infection and rise dramatically over the proceeding 2 weeks 
whereas IgM levels tend to be significantly lowered in secondary infection. 
In the early convalescent period of 6-10 days in secondary dengue IgM 
&IgG positive with ratio<1 22 (84.6%) showed higher positivity as IgM to 
second infection appears during this period. NS1, IgM &IgG showed 
positivity of 3(11.5%), IgG alone positive with thrombocytopenia 1(3.8%). 
As IgG is present in both current and past infections, presence of IgG alone 
does not indicate active infection. Hence it should be combined with platelet 
count. Only if the platelet count is lowered it indicates current infection. If it 
is normal, it shows past infection.  
In more than 10 days duration of secondary dengue IgM & IgG positive with 
ratio <1showed higher positivity (100%) which is due to the presence of 
IgM &IgG antibodies to the second infection. Susana vazquez et al83 
2007showed that IgM and IgG capture ELISA kits has high sensitivity and 
specificity and offers good alternative for dengue diagnosis. 
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ICTs for the detection of NS1, IgM, IgG antibodies have been developed by 
a number of commercial companies and have found wide applications 
because of their ease of use and rapidity of results. 
The case detection by ICT in this study was 10.2% for NS1, 17.7% for IgM, 
15.4% for IgG, whereas in ELISA it was 14.2%, 20.8% and 18.2% 
respectively. This clearly shows that case detection was more in ELISA. The 
ICT is found to be less sensitive to ELISA and gives false negative results in 
some cases.Cross reaction with other flaviviruses gives rise to false positives 
in some cases. In a study by RD Kulkarni et al6 2011 showed NS1 
positivity 29%, IgM positivity 50% and IgG positivity 2.8% in ICT.    
Masao et al in their study 84 2011  in Japan had said that  NS1 rapid test is 
suitable for lab diagnosis due to its reliability and rapidity  as it require only 
20 minutes for detection. But in view of its low sensitivity it is not suitable 
for screening purposes. 
In a study by Subhash C Arya 85 2011the ICT was highly sensitive (88%) 
and specific (98%). 
As diagnostic assays are usually evaluated in terms of Sensitivity and 
specificity that was calculated by 2x2 cross- tabulation, using a reference 
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standard (the test most widely used) is compared to determine diagnostic 
accuracy. 
Using ELISA as reference standard, the accuracy indices of the ICT were 
calculated. 
NS1 ICT had a sensitivity of 68%,specificity 99.3%, PPV 94.4%, NPV 
85.7%.Using chi-square test p value of <0.001 was  obtained which was 
found to be statistically significant. In a study by Subhash C Arya et al85 
2011 ICT showed 80-90% detection rate during first 7 days. In a Study by 
Vu Ty Han et al10, Thailand NS1 LFRT was found to be 100% specific and 
72% sensitive in primary than secondary dengue. 
In this study  the sensitivity and specificity of  IgM by ICT  was 
80.8%&98.9%,PPV-95.1% &NPV-95.1%.Using chi-square test ,p value of 
<0.05  was obtained  for IgM  which was found to be statistically significant. 
In a study by M Moorthy et al 162009 showed that the accuracy indices of 
ICT for IgM were 81.8%, 75.0%, 61% and 89.6% and concluded that ICT  
not to be used as stand alone test.  
In this study IgG in ICT showed Sensitivity of 81.3%, specificity 98.9%, 
PPV 94.1% & NPV  96.32% Using chi-square test p value of <0.001 was   
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obtained which was found to be statistically significant. Moorthy et al16  
2009 study with sensitivity of 87.5%, specificity 66.6%, PPV 72%, NPV 
83.9% concluded that ICT with moderate performance could not be used as 
stand alone test. 
WHO’s multicentric evaluation of Dengue antibody ICTs had IgM 
sensitivity from 20% to 100% & specificity from 77% to 98% when 
compared with reference ELISA.  
 Most of the patients were referred from various places and would 
have received few days treatment before reaching the hospital .The 
precise day of fever at the time of conducting the test could not be 
obtained in a large no of cases. In spite of this, NS1 alone was positive 
in 25% cases in this study. 
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SUMMARY 
• Seropositivity  of  Dengue  in 350  suspected cases  during  the study 
period  was   30% 
• The commonest age group affected by Dengue in this study was 0-10 
years in both sexes. 
• Dengue was predominant in Males when compared to Females with 
the ratio of  1.6:1 
• Dengue incidence in this study was more during the months of 
November, December 2011, January, May, June, July of 2012.  
• Of all the symptoms, fever was the commonest symptom followed by 
headache, myalgia, arthralgia, abdominal pain, vomiting, oliguria and 
rash. 
• Melena was the commonest bleeding manifestation followed by 
bleeding gums, hemetemesis and epistaxis in this study. 
• Dengue positive cases were classified into Dengue fever (48.5%), 
Dengue haemorrhagic fever (49.5%) and Dengue shock syndrome 
(2%) based on WHO guidelines. 
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• In the haematological parameters, Thrombocytopenia was associated 
more with Dengue positive cases. Platelet count of 50,000- 1 lakh was   
commonest range and majority were associated with DHF&DSS.   
• WBC count of <4000 was more commonly associated with DHF and 
DSS 
• Elevated Haematocrit level >45 was associated with DHF/DSS. 
• Biochemical parameters- AST and ALT were elevated in DF, DHF 
and DSS. 
• Of the USG findings, Gall bladder thickening, pleural effusion and 
ascites were seen in majority of Dengue haemorrhagic fever and 
Dengue shock syndrome. 
• In  this study  the incidence of  secondary dengue(55.1%) was more 
than primary dengue(44.9%)  with the ratio of 0.8:1 
• NS1 positivity was high in primary dengue followed by IgM alone. 
• In the acute period of 1-5 days in primary dengue NS1 antigen 
positivity was found to be higher followed by NS1 & IgM . 
• In the early convalescent period (6-10days) of Primary dengue IgM 
alone had higher positivity followed by IgM &IgG positive with ratio 
>1. 
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• In the late convalescent period (10 days) of primary dengue, IgM & 
IgG positive with ratio >1 alone showed positivity. 
• In secondary dengue, IgM & IgG positive with ratio<1 had higher 
positivity followed by NS1, IgM &IgG combination. 
• In the acute period of secondary dengue(1-5days) NS1, IgM &IgG 
positive  showed higher positivity followed by IgM ,IgG positive with 
ratio<1, IgG alone positive with thrombocytopenia  and lowered 
NS1&IgG positivity. 
• In the early convalescent period (6-10 days) IgM &IgG positive with 
ratio <1 showed higher positivity followed by the combination of 
NS1, IgM, IgG. 
• In late convalescent period (>10 days) IgM&IgG positive with ratio 
<1 alone showed higher sensitivity. 
• Case detection rate of ICT was 26.2%and ELISA was 30.5% for 350 
cases. 
• The percentage of case detection by ICT  for all the 3 parameters 
NS1,IgM and IgG was 10.2%,17.7% and 15.4%  and ELISA showed 
14.2%,20.8% and 18.2%.  
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• Sensitivity, Specificity, PPV and NPV for NS1 in ICT were 68%, 
99.3%, 94.4% and 85.7%. 
• Sensitivity ,Specificity ,PPV and NPV of IgM in ICT were 80.8%, 
98.9%, 95.1% and 95.1%. 
• Sensitivity,Specificity ,PPV and NPV of IgG in ICT were 81.3%, 
98.9%, 94.1% and  96.32%. 
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CONCLUSION 
 
As per the results of this study NS1 ELISA is highly sensitive and proved to 
be a valuable tool in the diagnosis of dengue particularly in the acute period. 
NS1 is a reliable marker in primary dengue and when combined with IgM 
improves the detection rate significantly in a single serum sample in the 
absence of   paired sera.  
For diagnosis of Dengue infection irrespective of duration of fever all the 
three (i.e) NS1, Dengue IgM and IgG by ELISA must be done .This helps to 
rule out infection and to avoid false negatives. Immuno capture ELISA is 
highly sensitive in the detection of dengue cases.  
Considering the moderate performance of ICT in this study the device 
cannot be used as a stand alone test and it should always be supplemented by 
ELISA for the diagnosis of Dengue infection.  
 Serological differentiation of primary and secondary can be arrived as 
per the results of the study as shown below 
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NS1 IgM IgG Category 
+ - - Primary dengue 
+ + - Primary dengue 
- + - Primary dengue 
- + + Primary dengue( IgM/IgG ratio>1) 
- - + 
Past infection-(Plateletcount &Total count 
normal). 
- - + Secondary dengue-(Platelet/Total count low) 
+ - + Secondary dengue 
+ + + Secondary dengue 
- + + Secondary dengue-(IgM/IgG ratio <1) 
 
Significant association of haematological profile and biochemical profile 
with seropositives in this study insists that these tests should be considered 
and given importance in the diagnosis and management of dengue. 
In conclusion, based upon the higher positivity of the NS1 ELISA both in 
primary and secondary dengue, this study gains public health importance 
because it suggests that NS1 antigen should be included along with routinely 
used antibody testing protocols for early detection and management of cases. 
ELISA is preferable for diagnostic purposes compared to ICT  and the use of  
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Immunocapture ELISA in the test panel for dengue will reduce the false 
Negativity thereby reducing the morbidity and mortality rate.   
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 APPENDIX - 1 
NS1 ELISA     
Sample dilution: 75 µl sample diluent + 75 µl of sample (1 in2) 
Control dilution: NC&PC diluted in the same ratio. 
Calibrator is also diluted in the same ratio as above in triplicate. 
Wash buffer (20x): 19 parts of distilled water added to 1 part of wash buffer 
concentrate. Quantity prepared depending upon the strips used for the test.  
IgM ELISA       
Serum pre dilution: Suitable test tubes used for dilution of serum, NC, PC, and 
CO .Wash buffer dilution:  19 parts of distilled water is mixed with 1 part of 
wash buffer concentrate. The required quantity is used and the remaining is 
discarded 
Sample dilution: 5µl Sample diluted with 500µl of sample diluent (1:100)  
Control dilution: NC, PC and cutoff calibrator diluted in the same manner as 
sample. 
 IgG ELISA          
Serum pre dilution: 
1. Serum 10µl + serum diluent 1000µl(1:100 dilution) done  
using suitable test tubes. 
2. Positive control, negative control and calibrators diluted in      the same  
manner 
 Wash buffer dilution: One Part of buffer concentrate added to 19 parts of 
distilled water. Total volume prepared as   required for the procedure. 
 
 
  
 
 
APPENDIX-2 
                           Immunochromatography card Test (n=107) 
Fever 
duration 
NS1 
alone 
IgM 
alone 
IgG NS1+IgM IgM+IgG NS1 
+IgG 
NS1+IgM+IgG 
1-5 
Days(60) 
20 4 1 6 
 
11 
 
2 
 
4 
 
6 – 10 
Days(36) 
0 7 
 
2 1 
 
25 
 
1 0 
 
> 10 
Days(11) 
0 1 4 
 
0 3 
 
0 0 
Total 
 
20 12 7        7 39 
 
3 
 
4 
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 PROFORMA 
                                                                                           Date:  
 
Name of the patient:                                                           Age / sex: 
 
Ward:                                                                                  ID no: 
 
Occupation:                                                                         Present address: 
 
Date of admission: 
 
Permanent address: 
 
H/o present illness: 
 
Fever:    
o Onset 
o Duration 
o Type of fever 
o Associated with rash/ myalgia/ arthralgia /abdominal 
pain/vomiting/headache 
o Bleeding tendencies 
 
H/O past illness: 
              - Travel to endemic areas. 
             -  Previous h/o fever with hospitalization 
             -  Living in endemic areas. 
 
Any relevant investigations done outside: 
 
H/O treatment: 
 
Nature of specimen collected: 
 
Date of collection: 
 
Investigation done: 
 
 PROTOCOL 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Selected Fever Cases 
Blood samples collected & received 
in Laboratory 
Rapid card test 
ELISA 
Dengue specific Antigen 
Dengue Specific IgM & IgG Antibodies 
Dengue specific Antigen 
Dengue Specific IgM & IgG Antibodies 
 
Hematological Markers 
1. Platelet count 
2. Packed cell volume 
3. Total Leucocyte count 
Biochemical Markers 
1. SGOT 
2. SGPT 
 WORKSHEET 
Collect Blood Samples from selected Cases 
 
 Separate serum by Centrifugation 
 
Subject to both ICT and ELISA 
 
Categorise ELISA Positive cases into10 and 20 dengue 
 
Compare Case detection by ELISA and ICT for serological markers 
                                                       
                  
Calculate Sensitivity, specificity, PPV, NPV for ICT using ELISA as 
Reference 
 
Collect clinical datas, haematological and biochemical profile for 
correlation 
                                                       
  
 
 
 CONSENT FORM 
Dr P.Malini, Post Graduate student in the Department of Microbiology, 
Coimbatore Medical College, Coimbatore, is studying on ‘Multivariate Analysis 
of Dengue in a Tertiary care Hospital’ regarding. 
I am, ___________________________ of age _____ years, sex - M/F, 
have been explained about the study. The venepuncture procedure, the risk 
involved and complications of the procedure were explained to me in my mother 
tongue. I have also been explained that the data obtained herein may be used for 
research and publication. I whole heartedly give my consent to participate in the 
study.  
 
Place: 
Date:                  Signature 
 
 
 S.No. 
IP 
/OP Name Age Sex Presenting Complaints Platelet  WBC HCT ALT AST USG ELISA     
    NS1 IgM IgG     
1 69212 Saraswathi 28 F 
Fr - 10 days ,AbdPain 5 
days,arthralgia,myalgia 20,000 3000 17.2 28 30 Normal N P P SEC DF 
2 70201 Karthick 16 M 
Fr - 4 days, 
myalgia,headache 56,000 3000 38.7 27 29 Normal N P P SEC DF 
3 73576 Rajkumar 33 M 
Fr-12 
days,Hemetemesis,Haem
aturia,myalgia,rash 23,000 3200 53.7 52 72 BILPE N P P SEC DHF 
4 73482 Ganesh 5 mch Fr - 5days,vomiting,rash 33,000 2000 45.5 25 27 Normal N p P SEC DF 
5 73486 Sangamithra 4 fch 
Fr - 10 days ,Melena 2 
days,headache 56000 3500 34.8 21 25 min PE GB thickening N p P SEC DHF 
6 73561 Elan go 11 mch Fr - 2 days ,Arthralgia 43000 3000 24 25 27 Normal P N N PRI DF 
7 73506 Vijaya 60 F 
Fr -10days, 
Alteredsensorium,arthral
gia,maylgia 89000 16100 32.7 45 89 Grade I MKD N p P PRI DF 
8 113 Sumaiya 5 fch 
Fr - 12DAYS, Melena 3 
episodes,rash,epitaxis 43000 3400 25 28 30 
GB wall thickning,min.R 
PE N p P SEC DHF 
9 351 Divyadharshni 21/2 fch 
Fr-7 
days,Headache,melena 13000 3600 27.3 97 142 hepatomegaly N p P SEC DHF 
10   Sanfiya 8 fch 
Fr-6 
days,Myalgia,vomiting,ra
sh,epistaxis 91000 3000 23.3 31 32 Normal N p P SEC DF 
11 795 Sanjay 8 mch 
Fr-7 days,Abdmn 
Pain,myalgia 19000 6000 24.7 33 35 GB wall thickening,R PE N p P SEC DHF 
12 941 Abbas ali 14 M 
Fr-1 week,Abdmn Pain 3 
days,Vomiting 1 
week,Bleeding gums 237000 3100 46 23 27 Mod.ascites N p P SEC DHF 
 13 548 Ajith 10 mch 
Fr-
6days,Myalgia,bleeding 
gums 47000 2800 27.6 37 39 Normal N p P SEC DF 
14 2236 Mohammed Safix 14 M 
Fr-3 
days,Arthralgia,myalgia 52000 3500 43 41 43 Normal p p P SEC DHF 
15 2767 Neelakandan 5 mch 
Fr-5 days,AbdmnPain 3 
days,Oliguria 40000 3000 45.5 43 45 GB thickening N p P SEC DHF 
16 2512 Gowrav Kumar 11 mch 
Fr-6 days,Adbdmn Pain 2 
days,Oliguria 3 days 56000 3600 51.1 47 49 GB thickening N p P SEC DF 
17 2805 Vanitha 18 F Fr-5 days, Arthralgia 84000 7000 52 51 53 GB thickening p p P SEC DHF 
18 2930 Varsha 5 fch 
Fr-6 days, Vomiting 3 
episode,Abdmn 
Pain,Oliguria 35000 3900 46 55 57 GB thickening,RPE, N p P SEC DSS 
19 4738 Maran 75 M 
Abdmn Pain, Fr-2 
days,myalgia 136000 2500 46 59 60 Normal P p P SEC DF 
20 4968 Vijayakumar 20 M Fr-3 days,myalgia 20000 3100 41.9 49 44 GB wall thickening,R PE  p N N pri DHF 
21 4144 Saraswathy 66 F 
Fr-7 
days,Arthralgia,myalgia 76000 3600 24 25 23 GB thickening N p P SEC DF 
22 5765 Jayamani 47 F 
Fr-5 days, 
Melena,purpurahardpala
tebleeding 50000 3800 24.6 30 31 Normal P N N PRI DHF 
23 6163 Samuel 22 M Fr-2 days,Arthralgia 35000 3950 42.2 27 30 R   PE P N N PRI DHF 
24 61653 Rajendran 27 M 
Fr-4 days,Bleeding gums 
2 days,myalgia 30000 3800 36.8 27 41 Normal N P P SEC DF 
25 9143 Haridharshini 4 fch 
Fr,Vomiting 6 
days,oliguria 83000 2000 38.2 28 25 0 N p P SEC DF 
26 18828 Ansiya 8 fch 
Fr-11 days,Vomiting 1 
day 53000 3100 38.8 29 22 GB thickening N P P SEC DHF 
 27 11348 Nuthun 26 M 
Fr-5 
days,Vomiting,Arthralgia,
Haematuria,Epitaxis 36000 2600 48.6 45 50 R minimal PE P N N PRI DHF 
28 11943 Velmurugan 32 M 
Fr-4 
days,arthralgia,myalgia,b
leeding gums 39000 2000 45.7 22 24 Normal P N N PRI DF 
29 68327 Irfanahmed 6 mch Fr-6 days,Myalgia 33000 3910 36 25 26 Thickened GB,,Bil.PE N P P SEC DHF 
30 72407 Priyanka 8 fch Fr-5 days,arthralgia 31000 3700 38.5 41 43 - p N N PRI DF 
31   Anandkumar 14 M 
Fr-
5days,Hemetemesis,myal
gia 55000 3000 40 42 40 Normal P N N PRI DF 
32 1E+05 Mansurali 24 M Fr-7 days,Haematuria 66000 3000 45.5 35 30 
GB wall thickening 
p p P SEC DHF 
33 18433 Sagana 5 fch Fr-6 days,myalgia 82000 6000 46 25 27 
minimal R pleural 
effusion p p P SEC DHF 
34 19258 Bathri 3 fch 
Fr-11days, Edima 2 
days,hemetemesis,rash 48000 3500 46.4 20 25 GB wall thickening N p P SEC DHF 
35 9676 Karthick 3 fch Fr-4 days,abd.pain 74000 8000 48 58 55 diffuse GB thickening p N P SEC DHF 
36 20502 Vignesh 6 mch 
Fr-4 
daysvomiting,maylgia 28000 8200 45.8 26 21 
minimal R PE,GB wall 
thickening p P N PRI DHF 
37 20432 Rahul 3 mch Fr-6days,vomiting 27000 4900 37.5 20 25 
minimal R PE,GB wall 
thickening N p P SEC DHF 
38 24426 Vinithkumar 3 mch 
Fr-7 days, Abdmn 
Pain,Nausea Vomiting 17000 3100 36 26 28 GB wall thickening N p P SEC DHF 
39 24481 Prahalad 30 M Fr-6 days,myalgia 49000 4000 48 43 47 Normal N p P SEC DHF 
 40 26097 Harichander 2 mch Fr-8 days, Abdmn Pain, 60000 5000 33 35 30 - N p P SEC DF 
41 2E+05 Ashok kumar 17 M 
Fr-8 
days,arthralgia,myalgia 37000 3500 42 37 30 GB thickening N p P SEC DHF 
42 35207 Balu 36 M Fr-4 days,  Arthralgia 45000 3800 33.1 43 45 Hepatomegaly P p P SEC DF 
43 35906 Ramesh 38 M 
Fr-7 days, Vomiting 1 
episode,Myalgia,bleeding
gums 20000 10600 48.5 28 29 GB wall thickening P p P SEC DHF 
44 32911 Manoba 9 mch 
Fr-5 day Abdmn Pain, 
Vomiting,headache,mele
na 37000 8200 41 25 27 GB thickening N p P SEC DHF 
45 32910 Jeevasri 10 fch 
Fr with Chills,Abdmn Pain 
4days,myalgia 31000 2800 33.7 29 25 Bil.PE,min.FF abdomen P N N PRI DHF 
46 32075 Meenambigai 6 fch 
Fr-4 
days,vomiting,myalgia 26000 3200 37.2 28 21 GB wall thcickened P p P SEC DHF 
47 7815 Kumaravel 7 mch 
Fr-7 
days,vomiting,myalgia 49000 4500 32 27 28 Normal N P P SEC DHF 
48 7816 Vetrivel 4 mch 
Fr-7 days,Abdmn 
pain,Vomiting 55000 3200 40 23 25 normal N P P SEC DF 
49 33544 Arunvijay 15 M 
Fr-11days, 
abd.pain,myalgia 17000 3100 42 36 32 min.RPE,Asscites N P P SEC DHF 
50 35493 Damodaran 12 M 
Fr-12 
days,Myalgia,Arthralgia 129000 2200 33.6 27 24 Gb wall edematous N P P SEC DF 
51 35095 Saranya 16 F Fr-4 days,artralgia 17000 5700 32.2 45 48 
GB edematous,Bil.PEFF 
abdomen &pelvis P N N PRI DHF 
52 35184 sathish 24 M 
Fr-4 
days,Myalgia,Arthralgia,h
eadache,vomiting 46000 5000 52.5 30 32 GB wall edematous p p N PRI DF 
 53 35240 Ashok kumar 8 M 
Fr-6days,Vomiting 5 
days,Melena,Abdmn Pain 36000 3200 33.7 35 30 
GB wall edematous 
,Bil.PE,ascites N p P SEC DHF 
54 35375 Valliyammal 60 F Fr-5 days,  Arthralgia 35000 7000 35 32 30 GB contracted, P N N PRI DF 
55 35376 Mohammedhussain 15 M Fr-11days,myalgia 17000 3800 50.8 45 48 
GB thickening, 
N p P SEC DHF 
56 31346 Murugan 32 M 
Fr-4 
days,dysuria,headache,ar
thralgia 61000 2600 42.5 29 30 - P p N PRI DF 
57 35333 Navanethan 4 mch 
Fr-11 
days,vomiting,myalgia 45000 3500 40.2 28 30 GB thickened N P P SEC DF 
58 35236 Selvakrishnan 1 mch Fr-4 days,headache 56000 14000 39.5 32 80 NA p P P SEC DF 
59 33510 Logeswaran 19 M 
Fr-7 days, 
Myalgia,arthralgia 24000 5100 19 25 22 Normal N p P SEC DF 
60 32336 Manikandan 32 M 
Fr-1 weeks,Arthralgia 10 
days 87000 3000 36 42 45 NA N p P SEC DF 
61 34418 Shankar 26 M 
Fr-2 
days,Myalgia,arthralgia 7000 3000 49.4 24 26 Hepatomegaly p P P SEC DF 
62 34579 Sivakumar 20 M 
Fr-12 days, 
Vomiting,Melena 3 days 14000 2900 45.6 28 30 minimal R PE ,Ascites N P P SEC DHF 
63 36503 Dharshini 7 fch 
Fr-5 days,Refusal of 
feeds 3 days,melena 1 
day 55000 13400 27.6 32 40 Hepatomegaly N N P SEC DF 
64 36331 Jithin Samuel 10 mch Fr-4 days,arthralgia 87000 330000% 33 37 35 
hepatomegaly,     GB 
contracted N N P SEC DF 
65 36450 Divya 21 F 
Fr-5days, rash, Abdmn 
pain 88000 3600 45.9 35 32 GB thickened P N N PRI DHF 
66 36394 Vijayaraghavan 1.5 mch 
Fr-5 days,Abdmn Pain 4 
days 360000 3300 48.8 42 43 
GB contracted, 
P N N PRI DHF 
 67 36436 Bhagyalakshmi 18 F 
Fr-5 days, Vomiting 3 
days,Adbmn pain 4 days 68000 3600 46.9 30 42 
GB wall thickening 
P N N PRI DHF 
68 32482 Amirtha 17 F Fr-10 days,arthralgia 200000 6500 31 25 27 normal N P N PRI DF 
69 34794 Amirtham 40 F 
Fr-5 
days,arthralgia,myalgia 100000 4000 42 43 45 NA P N N PRI DF 
70 35040 Priyadharshini 12 fch Fr-5 days,arthralgia 111000 4800 12.7 25 27 hepatomegaly P N N PRI DF 
71 37045 Deepika 17 F Fr-3 days,arthralgia 68000 6200 22.5 26 25 normal P N N PRI DF 
72 33204 Kelvin 46 M 
Fr,Abdmn pain 3 
days,myalgia 70000 2500 32 23 25 - p N N PRI DF 
73 35331 AyishaRithiga 23 F Fr-3 days,Arthralgia 100000 1500 12.7 25 25 Normal P N N PRI DF 
74 34531 Munna 23 M 
Fr- 6 days,vomiting, 
abdmn pain,arthralgia 16000 6300 33.7 29 27 Normal N N P SEC DF 
75 2E+05 Dharshan 1 mch 
Fr-5 days,  Abdmn 
pain,hemetemesis 65000 2500 47 50 53 
 GB thickening,pleural 
effusion,ascites. p N p SEC DSS 
76 78957 Kamala 22 F Fr-10 days,Myalgia 27000 3400 32.8 26 21 Normal N P N PRI DF 
77 73621 Amudhavalli 22 F 
Fr-3 
days,Myalgia,Arthralgia 13200 4800 36.9 25 28 NA P p P SEC DF 
78 72846 Yamuna 6 fch Fr-5 days,vomiting 113000 5600 28 24 26 
  ,R PE 
p P N PRI DHF 
79 7973 Aravivel 12 mch 
Fr-5 days,Myalgia,Abdmn 
pain,Melena 45000 6000 34 42 43                 GBthickening N p P SEC DHF 
80 7862 Kalingaraj 13 M Fr-7 days,vomiting 39000 2400 46.6 35 37 GB thickening N p P PRI DHF 
 81 70488 Jaya 21 F Fr-3 days, 63000 1700 38.5 32 39 Normal N p N PRI DF 
82 7389 Mani 34 M 
Fr-6 
days,Myalgia,Nausea,Vo
miting 14000 3000 35 29 27 
- 
N p P PRI DF 
83 23275 Nitesesh 6 mch Fr-10 days 94000 6000 36 28 29 - N p N PRI DF 
84 71821 Dinakaran 8 mch 
Fr-15 days,Abdmn Pain 3 
days 190,000 9800 30 25 27 Normal N p P PRI DF 
85 62920 Poongodi 7 fch Fr-5 days,Abdmn pain, 82000 2300 38.6 27 29 Normal P N N PRI DF 
86 7288 Maheswari 10 fch Fr-3 days,myalgia 70000 3000 49.7 28 30 
hepatomegaly,     PE 
P p N PRI DHF 
87 32266 Lakshmanan Babu 8 mch Fr-5 days 52000 2000 39 29 30 Normal P N N PRI DF 
88 7173 Umadevi 9 fch 
Fr-3 days,Melena 1 day, 
Oliguria 2 days 34000 1700 48 25 27 FF abdomen  P p P SEC DHF 
89 31102 Priya 23 F Fr-3 days,  36000 3000 35 28 30 - P N N PRI DF 
90 28551 lalitha 15 F Fr- 5 days, 72,000 2000 38 25 27 Normal P N N PRI DF 
91 32394 Sathish Kumar 38 M Fr-5 days,Vomiting 60000 5200 46 30 42 minimal R PE  P N N PRI DHF 
92 67696 Sikinder 35 M 
Fr-5 days,Abdmn Pain 2 
days,arthralgia 37000 3000 29.4 25 27 
Normal 
P p N PRI DF 
93 68299 Indurekha 13 F Fr - 3 days,arthralgia 57,000 7000 30 33 35 - P p N PRI DF 
94 71223 Venkatprabu 8.12 mch 
Fr-7 days,Melena 2 
days,abdominal pain 29000 3000 45.3 25 29 bil.PE N p N PRI DHF 
 95 3320 Gopalakrishnan 10 mch 
Fr-5 days,Vomiting 3 
days, Melena 3 days 73000 3000 35 27 29 
ascites 
P N N PRI DHF 
96 31647 Venkatachalam 30 M 
Fr-4 days, Abdmn Pain, 
Giddiness,arthralgia 15000 3000 40 29 30 - P N N PRI DF 
97 30889 Bharath 10 mch 
Fr-5 days, Abdmn 
Pain,Melena 80000 3800 46 27 29 
pleural effusion 
P p P SEC DHF 
98 3E+05 Karthick 11 M 
Fever 5 days, Headache 5 
day,Melena 4 days, 
Abdmn Pain 32000 2600 37.5 30 35 bil.PE P p P SEC DHF 
99 31346 Murugesan 32 M 
Fr-6 days, Abdmn 
Pain,Dysuria 4 days 61000 2600 45.5 31 35 
pleural effusion 
N p N PRI DHF 
100 31344 Ashok 10 mch 
Fr-4 days, Vomiting,Poor 
appetite,Myalgia, Abdmn 
pain 35000 3100 57.3 32 30 
ascites 
P N N PRI DHF 
101 33233 Kaviraj 16 M 
Fr-7 days Abdmn 
pain,arthralgia 73000 2700 42 20 25 
pleural effusion 
N p P PRI DHF 
102 34282 Dilfar 5 mch 
Fr-7 days,Vomiting 2 
days 22000 3500 46.5 25 27 minimal R PE N p N PRI DHF 
103 28819 sakthivel 27 M Fr-6 days,Myalgia  48000 2900 39 23 25 - N p N PRI DF 
104 33367 Amritha Iniya 7 fch 
Fr-3 days, Vomiting, 
Abdmn pain 21000 5600 39.8 43 47 ascites N N P SEC DHF 
105 33739 Thangomani 40 F 
Fr-2 days,Burning 
Micturition,Myalgia 31000 2400 36 25 24 normal p p N PRI DF 
106 33755 Subramani 62 M Fr-12days, Myalgia 57000 3000 33 25 27 normal N P P SEC DF 
107 33855 NavaneethaKrishnan 12 mch 
Fr-5 days,Myalgia,Abdmn 
pain,Melena 28000 3500 48 29 30 
ascites 
N N P SEC DHF 
Note: P-Positive, N - Negative, M-Male,F-Female,mch-MaleChild,fch-FemaleChild 
 
            Multivariate Analysis of Dengue in a Tertiary Care Hospital. 
                                                                      
 ABSTRACT 
Background: Dengue is a viral infection with potential fatal complications. It is considered as 
one of the worlds major emerging tropical diseases. More than 2.5 billion people are at risk of 
infection and more than 100 countries have endemic transmission. The emergence and 
reemergence of dengue is attributed to demographic and societal changes with increased 
movement of people from endemic areas and inadequate mosquito control measures. It is an 
emerging disease in Tamilnadu. Dengue virus is an enveloped ssRNA virus of 45-50 nm 
belonging to Genus flavivirus and Family flaviviridae. Dengue is transmitted by Aedes aegypti 
mosquitoes. It causes wide spectrum of illness ranging from undifferentiated illness to Dengue 
haemorrhagic fever and Dengue shock syndrome. Specific IgM and IgG detection has been the 
mainstay of diagnosis for a long time. Dengue specific antigen is found to be highly specific and 
reliable marker from the first day of diagnosis. Aim and objectives: To study the multivariate 
analysis of Dengue with serological differentiation of primary(PD) and secondary dengue(SD), 
comparative evaluation of  Immunochromatography(ICT) with Immunocapture Enzyme Linked 
Immuno Sorbent Assay (ELISA) and special emphasis on Nonstructural protein( NS1) antigen as 
an early diagnostic marker . To correlate Dengue clinically with haematological and biochemical 
profile. Materials and methods: After taking informed consent, blood was drawn from three 
hundred and fifty suspected cases and were subjected to both ICT and ELISA.ELISA positive 
cases were analysed further. Accuracy indices of ICT were calculated using ELISA as reference 
assay. Results: Out of 350 samples tested ,107 were positive by ELISA (30.5%) for one or more 
serological markers. The common age group affected were 0-10 years in both sexes with male: 
female ratio of 1.6:1.Incidence was high during November to December 2011& January , May 
,june & July 2012. Clinically seropositives were classified as Dengue fever, Dengue 
haemorrhagic fever and Dengue shock syndrome. There was significant association of 
thrombocytopenia, HCT and WBC count with Dengue fever, DHF and DSS. The107 
seropositives by ELISA were categorized as primary and secondary dengue based on duration of 
fever and serological markers. Out of 107, 27 were positive for NS1only, 9 were positive for 
IgM alone, only 6 showed IgG alone. More than one marker was detected in the remaining 65 
samples .In 48 primary dengue cases NS1 had higher positivity and in secondary dengue 
IgM&IgG ratio >1 had higher positivity. Sensitivity, specificity, PPV and NPV of the ICT were 
calculated using ELISA as reference for individual markers which showed moderate 
performance. Haematological and biochemical profile also showed statistical significance in 
association with Dengue fever, DHF and DSS. Conclusion: Inclusion of NSI in the routine 
diagnosis of dengue increases the detection rate of cases significantly in the early period. 
Irrespective of fever duration, all the three ELISA must be done to rule out Dengue infection like 
NS1, IgM, and IgG. Immunocapture ELISA is reliable and sensitive than ICT even though it is 
highly specific. Haematological and biochemical tests should also be given importance along 
with serological markers for dengue diagnosis and management. 
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